ZA200307466B - Novel tyrosine kinase inhibitors. - Google Patents
Novel tyrosine kinase inhibitors. Download PDFInfo
- Publication number
- ZA200307466B ZA200307466B ZA200307466A ZA200307466A ZA200307466B ZA 200307466 B ZA200307466 B ZA 200307466B ZA 200307466 A ZA200307466 A ZA 200307466A ZA 200307466 A ZA200307466 A ZA 200307466A ZA 200307466 B ZA200307466 B ZA 200307466B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- ethylamino
- pyridin
- phenyl
- hydroxy
- Prior art date
Links
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title description 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 151
- 229910052739 hydrogen Inorganic materials 0.000 claims description 116
- 239000001257 hydrogen Substances 0.000 claims description 107
- 125000000217 alkyl group Chemical group 0.000 claims description 102
- 150000002431 hydrogen Chemical class 0.000 claims description 75
- -1 sulfoxy, sulfonyl Chemical group 0.000 claims description 74
- 125000001072 heteroaryl group Chemical group 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 45
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 43
- 125000005843 halogen group Chemical group 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 39
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 35
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 27
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 25
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 24
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000002780 morpholines Chemical class 0.000 claims description 6
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229940022353 herceptin Drugs 0.000 claims description 5
- XPTAUSRPHWOZPN-UHFFFAOYSA-N morpholin-4-yl hydrogen sulfate Chemical group OS(=O)(=O)ON1CCOCC1 XPTAUSRPHWOZPN-UHFFFAOYSA-N 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- OTOIUCLFSQHFOX-UHFFFAOYSA-N 3-sulfonylmorpholine Chemical group O=S(=O)=C1COCCN1 OTOIUCLFSQHFOX-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229930013356 epothilone Natural products 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 229940084651 iressa Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 4
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims description 3
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical group C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 3
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 claims description 2
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 claims description 2
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 108010069236 Goserelin Proteins 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001220 amsacrine Drugs 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 2
- 229960000978 cyproterone acetate Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
- 229950004203 droloxifene Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 2
- 229960004039 finasteride Drugs 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003690 goserelin acetate Drugs 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- 229960004296 megestrol acetate Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims description 2
- 229960002653 nilutamide Drugs 0.000 claims description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LWELCYJSAYQTOX-UHFFFAOYSA-N 1-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]-N-(2-fluoroethoxy)piperidine-4-carboxamide Chemical compound N=1C=2C(C)=CC(N3CCC(CC3)C(=O)NOCCF)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 LWELCYJSAYQTOX-UHFFFAOYSA-N 0.000 claims 1
- BKRADANXACAJKT-UHFFFAOYSA-N 2-[4-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazin-1-yl]acetonitrile Chemical compound N=1C=2C(C)=CC(N3CCN(CC#N)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 BKRADANXACAJKT-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- NIAVSXKTUHEZFR-UHFFFAOYSA-N 2-fluoroethyl 4-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazine-1-carboxylate Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)OCCF)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 NIAVSXKTUHEZFR-UHFFFAOYSA-N 0.000 claims 1
- CMYZQDNEXKMVAP-UHFFFAOYSA-N 3-(1H-benzimidazol-2-yl)-4-[[2-(3-bromophenyl)-2-hydroxyethyl]amino]-1H-pyridin-2-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=CC=C3N=2)=C1NCC(O)C1=CC=CC(Br)=C1 CMYZQDNEXKMVAP-UHFFFAOYSA-N 0.000 claims 1
- GRFOHUBBUMAJMM-UHFFFAOYSA-N 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide Chemical compound C=1C2=CC=CC=C2N=C(N)C=1CCC(=O)N(C)C1CCCCC1 GRFOHUBBUMAJMM-UHFFFAOYSA-N 0.000 claims 1
- QLARNLBZNLHNOT-UHFFFAOYSA-N 3-[6-(aminomethyl)-4-methyl-1H-benzimidazol-2-yl]-4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(CN)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 QLARNLBZNLHNOT-UHFFFAOYSA-N 0.000 claims 1
- HGDHHEZBLVABGA-UHFFFAOYSA-N 3-[6-[4-(2-chloroacetyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)CCl)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 HGDHHEZBLVABGA-UHFFFAOYSA-N 0.000 claims 1
- CLWRLQRRLJJWJG-JOCHJYFZSA-N 4-[2-[4-[[(2S)-2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazine-1-carbaldehyde Chemical compound C1=C(Br)C(OC)=CC=C1[C@H](O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCN(CC2)C=O)C(=O)NC=C1 CLWRLQRRLJJWJG-JOCHJYFZSA-N 0.000 claims 1
- AMJILRTVLRYXLQ-HXUWFJFHSA-N 4-[[(1S)-2-hydroxy-1-phenylethyl]amino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C1([C@@H](CO)NC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2C=NC=C2)=CC=CC=C1 AMJILRTVLRYXLQ-HXUWFJFHSA-N 0.000 claims 1
- QCDSKOUKWJFTKU-OFNKIYASSA-N 4-[[(1S,2R)-1-hydroxy-2,3-dihydro-1H-inden-2-yl]amino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound Cc1cc(cc2[nH]c(nc12)-c1c(N[C@@H]2Cc3ccccc3[C@@H]2O)cc[nH]c1=O)-n1ccnc1 QCDSKOUKWJFTKU-OFNKIYASSA-N 0.000 claims 1
- LQRBWXDBMNHGCK-FQEVSTJZSA-N 4-[[(2R)-2-hydroxy-2-phenylethyl]amino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C1([C@@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2C=NC=C2)=CC=CC=C1 LQRBWXDBMNHGCK-FQEVSTJZSA-N 0.000 claims 1
- VULKTEGKCCHBBY-IBGZPJMESA-N 4-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1CCOCC1)C1=CC=CC=C1 VULKTEGKCCHBBY-IBGZPJMESA-N 0.000 claims 1
- SLYJOQJAIBXMFF-FQEVSTJZSA-N 4-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]-3-(4-methyl-6-piperidin-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1CCCCC1)C1=CC=CC=C1 SLYJOQJAIBXMFF-FQEVSTJZSA-N 0.000 claims 1
- DWXRRSODJNHKQF-FQEVSTJZSA-N 4-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]-3-[4-methyl-6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1CN(C)CCN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3N[C@H](CO)CC=3C=CC=CC=3)=O)C2=C1 DWXRRSODJNHKQF-FQEVSTJZSA-N 0.000 claims 1
- MZHLCADPMKFBDN-KRWDZBQOSA-N 4-[[(2S)-1-hydroxy-3-pyridin-4-ylpropan-2-yl]amino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1C=NC=C1)C1=CC=NC=C1 MZHLCADPMKFBDN-KRWDZBQOSA-N 0.000 claims 1
- LUSNIDFBBMXWAZ-XMSQKQJNSA-N 4-[[(2S)-2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[(2R)-2-(hydroxymethyl)morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1=C(Br)C(OC)=CC=C1[C@H](O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2C[C@H](CO)OCC2)C(=O)NC=C1 LUSNIDFBBMXWAZ-XMSQKQJNSA-N 0.000 claims 1
- ODUJFBNSLMAOSE-AUSIDOKSSA-N 4-[[(2S)-2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[(2R)-2-(methoxymethyl)morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1CO[C@@H](COC)CN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3NC[C@@H](O)C=3C=C(Br)C(OC)=CC=3)=O)C2=C1 ODUJFBNSLMAOSE-AUSIDOKSSA-N 0.000 claims 1
- PKNHVWJAADMUFX-AUSIDOKSSA-N 4-[[(2S)-2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[(2R)-2-(methoxymethyl)morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1CO[C@@H](COC)CN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3NC[C@@H](O)C=3C=C(Cl)C(OC)=CC=3)=O)C2=C1 PKNHVWJAADMUFX-AUSIDOKSSA-N 0.000 claims 1
- XNQQOBWDWJLPKE-XMSQKQJNSA-N 4-[[(2S)-2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[(2S)-2-(fluoromethyl)morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1=C(Cl)C(OC)=CC=C1[C@H](O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2C[C@@H](CF)OCC2)C(=O)NC=C1 XNQQOBWDWJLPKE-XMSQKQJNSA-N 0.000 claims 1
- PKNHVWJAADMUFX-WMZHIEFXSA-N 4-[[(2S)-2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[(2S)-2-(methoxymethyl)morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1CO[C@H](COC)CN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3NC[C@@H](O)C=3C=C(Cl)C(OC)=CC=3)=O)C2=C1 PKNHVWJAADMUFX-WMZHIEFXSA-N 0.000 claims 1
- IIJGLRWTELJRPH-OPAMFIHVSA-N 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-[(2R)-2-methylmorpholin-4-yl]-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1CO[C@H](C)CN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3NC[C@@H](O)C=3C=C(Cl)C=CC=3)=O)C2=C1 IIJGLRWTELJRPH-OPAMFIHVSA-N 0.000 claims 1
- KPFSRAAWPJUHQV-OAQYLSRUSA-N 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-(5,6-dihydro-4H-pyrimidin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2C=NCCC2)=CC=CC(Cl)=C1 KPFSRAAWPJUHQV-OAQYLSRUSA-N 0.000 claims 1
- FSDYMRXZPHZFJS-UHFFFAOYSA-N 4-[[2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C1=C(Br)C(OC)=CC=C1C(O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCOCC2)C(=O)NC=C1 FSDYMRXZPHZFJS-UHFFFAOYSA-N 0.000 claims 1
- IMMXVSIPHLGTTG-UHFFFAOYSA-N 4-[[2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[4-(3-fluoropropyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1=C(Br)C(OC)=CC=C1C(O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCN(CCCF)CC2)C(=O)NC=C1 IMMXVSIPHLGTTG-UHFFFAOYSA-N 0.000 claims 1
- MQPZCABORBJAFW-UHFFFAOYSA-N 4-[[2-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCOCC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=C(F)C(Cl)=C1 MQPZCABORBJAFW-UHFFFAOYSA-N 0.000 claims 1
- MQKSVRLGJFYTRI-UHFFFAOYSA-N 4-[[2-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-piperazin-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCNCC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=C(F)C(Cl)=C1 MQKSVRLGJFYTRI-UHFFFAOYSA-N 0.000 claims 1
- IYAZTZOPWLFGSM-UHFFFAOYSA-N 4-[[2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C1=C(Cl)C(OC)=CC=C1C(O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCOCC2)C(=O)NC=C1 IYAZTZOPWLFGSM-UHFFFAOYSA-N 0.000 claims 1
- VTMIHYCOXBGSOX-UHFFFAOYSA-N 4-[[2-(3-chloro-4-methoxyphenyl)-2-hydroxyethyl]amino]-3-[6-[4-(3-fluoropropyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound C1=C(Cl)C(OC)=CC=C1C(O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCN(CCCF)CC2)C(=O)NC=C1 VTMIHYCOXBGSOX-UHFFFAOYSA-N 0.000 claims 1
- UIUYQDFIVJOTTH-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-piperazin-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCNCC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 UIUYQDFIVJOTTH-UHFFFAOYSA-N 0.000 claims 1
- GLPQSWLXLBIVRM-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(6-imidazol-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C=1C=CC(Cl)=CC=1C(O)CNC=1C=CNC(=O)C=1C(NC1=C2)=NC1=CC=C2N1C=CN=C1 GLPQSWLXLBIVRM-UHFFFAOYSA-N 0.000 claims 1
- ODKOFIIUMZVPOY-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-[4-(2-methylsulfonylacetyl)piperazin-1-yl]-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)CS(C)(=O)=O)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 ODKOFIIUMZVPOY-UHFFFAOYSA-N 0.000 claims 1
- IAOSNXWODOEZQA-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-[4-(2-methylsulfonylethyl)piperazin-1-yl]-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CCS(C)(=O)=O)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 IAOSNXWODOEZQA-UHFFFAOYSA-N 0.000 claims 1
- UIBLHEZWESDKHO-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-[4-(2-thiomorpholin-4-ylacetyl)piperazin-1-yl]-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)CN3CCSCC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 UIBLHEZWESDKHO-UHFFFAOYSA-N 0.000 claims 1
- BDECAGGTSQFWTL-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-[4-(3,4,4-trifluorobut-3-enyl)piperazin-1-yl]-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CCC(F)=C(F)F)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 BDECAGGTSQFWTL-UHFFFAOYSA-N 0.000 claims 1
- VQPODECQMREPQU-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-[4-(2,2-difluoroacetyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)C(F)F)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 VQPODECQMREPQU-UHFFFAOYSA-N 0.000 claims 1
- ODZVOOVRXLCZEN-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-[4-(2-hydroxy-2-methylpropyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC(C)(C)O)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 ODZVOOVRXLCZEN-UHFFFAOYSA-N 0.000 claims 1
- DWYUYEUFJJPGLV-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-[4-(3-fluoro-2-hydroxypropyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC(O)CF)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 DWYUYEUFJJPGLV-UHFFFAOYSA-N 0.000 claims 1
- VUVAXIBXIAPBBM-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-[4-(3-fluoropropyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CCCF)CC3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 VUVAXIBXIAPBBM-UHFFFAOYSA-N 0.000 claims 1
- KKACLEOGRMSWFM-UHFFFAOYSA-N 4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[6-[4-(4-fluorobutanoyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)CCCF)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 KKACLEOGRMSWFM-UHFFFAOYSA-N 0.000 claims 1
- SJEQKFKYXGQTRS-UHFFFAOYSA-N 4-[[2-(7-bromo-2,3-dihydro-1-benzofuran-5-yl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one Chemical compound C=1C=2NC(C=3C(NC=CC=3NCC(O)C=3C=C(Br)C=4OCCC=4C=3)=O)=NC=2C(C)=CC=1N1CCOCC1 SJEQKFKYXGQTRS-UHFFFAOYSA-N 0.000 claims 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 1
- AGZWYQQHRJRPIX-VPMGYIILSA-N BrC=1C=C(C=CC1OC)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O Chemical compound BrC=1C=C(C=CC1OC)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O AGZWYQQHRJRPIX-VPMGYIILSA-N 0.000 claims 1
- LCASSGCXTUGCDS-ABQCGAOJSA-N ClC=1C=C(C=CC1)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O Chemical compound ClC=1C=C(C=CC1)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O LCASSGCXTUGCDS-ABQCGAOJSA-N 0.000 claims 1
- BLMUEZVDGQGLQT-VPMGYIILSA-N ClC=1C=C(C=CC1OC)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O Chemical compound ClC=1C=C(C=CC1OC)[C@@H](CNC1=C(C(NC=C1)=O)C1=NC2=C(N1)C=C(C=C2C)N2[C@H](C(OCC2)O)C)O BLMUEZVDGQGLQT-VPMGYIILSA-N 0.000 claims 1
- OWADAENBHRXWNV-UHFFFAOYSA-N N-[1-[2-[4-[[2-(3-bromophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperidin-4-yl]-2-hydroxyacetamide Chemical compound N=1C=2C(C)=CC(N3CCC(CC3)NC(=O)CO)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Br)=C1 OWADAENBHRXWNV-UHFFFAOYSA-N 0.000 claims 1
- HZQLLKQPXMHIMZ-UHFFFAOYSA-N N-[1-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperidin-4-yl]-2-fluoroacetamide Chemical compound N=1C=2C(C)=CC(N3CCC(CC3)NC(=O)CF)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 HZQLLKQPXMHIMZ-UHFFFAOYSA-N 0.000 claims 1
- QKBUDEHLHMPUOI-UHFFFAOYSA-N N-[1-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3NCC(O)C=3C=C(Cl)C=CC=3)=O)C2=C1 QKBUDEHLHMPUOI-UHFFFAOYSA-N 0.000 claims 1
- 125000005122 aminoalkylamino group Chemical group 0.000 claims 1
- XMRDJZYWIDOPTO-UHFFFAOYSA-N chembl231305 Chemical compound N=1C=2C(C)=CC(N3C=NC=C3)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(F)=C1 XMRDJZYWIDOPTO-UHFFFAOYSA-N 0.000 claims 1
- NOTYZJDDBQLRNQ-SFHVURJKSA-N chembl245306 Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1C=NC=C1)C1=CC=C(Cl)C=C1 NOTYZJDDBQLRNQ-SFHVURJKSA-N 0.000 claims 1
- QZBMIUISTXROQE-SFHVURJKSA-N chembl245366 Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1C=NC=C1)C1=CC=CC(Cl)=C1 QZBMIUISTXROQE-SFHVURJKSA-N 0.000 claims 1
- SVOBCURLIYHUOI-KRWDZBQOSA-N chembl245369 Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1C=NC=C1)C1=CC=CC=C1Br SVOBCURLIYHUOI-KRWDZBQOSA-N 0.000 claims 1
- WASNZPFVELUKFM-HXUWFJFHSA-N chembl389605 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2C=NC=C2)=CC=CC(Cl)=C1 WASNZPFVELUKFM-HXUWFJFHSA-N 0.000 claims 1
- IKELJUFKSAJTLQ-SFHVURJKSA-N chembl391158 Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(C=C(C=2N=1)C)N1C=NC=C1)C1=CC=CC(F)=C1 IKELJUFKSAJTLQ-SFHVURJKSA-N 0.000 claims 1
- WASNZPFVELUKFM-FQEVSTJZSA-N chembl425303 Chemical compound C1([C@@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2C=NC=C2)=CC=CC(Cl)=C1 WASNZPFVELUKFM-FQEVSTJZSA-N 0.000 claims 1
- IXRUDPNBDKEDFQ-UHFFFAOYSA-N chembl428222 Chemical compound N=1C=2C(C)=CC(N3C=NC=C3)=CC=2NC=1C(C(NC=C1)=O)=C1OCC1=CC=CC=N1 IXRUDPNBDKEDFQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims 1
- 229910052754 neon Inorganic materials 0.000 claims 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims 1
- NDATWLNHARHTNE-UHFFFAOYSA-N prop-2-ynyl 4-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazine-1-carboxylate Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)OCC#C)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 NDATWLNHARHTNE-UHFFFAOYSA-N 0.000 claims 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 claims 1
- 102220047090 rs6152 Human genes 0.000 claims 1
- XPMYBIMPBQCZMX-UHFFFAOYSA-N tert-butyl 4-[2-[4-[[2-(3-bromo-4-methoxyphenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazine-1-carboxylate Chemical compound C1=C(Br)C(OC)=CC=C1C(O)CNC1=C(C=2NC3=CC(=CC(C)=C3N=2)N2CCN(CC2)C(=O)OC(C)(C)C)C(=O)NC=C1 XPMYBIMPBQCZMX-UHFFFAOYSA-N 0.000 claims 1
- WDPFLACZLYWILA-UHFFFAOYSA-N tert-butyl 4-[2-[4-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-oxo-1H-pyridin-3-yl]-7-methyl-3H-benzimidazol-5-yl]piperazine-1-carboxylate Chemical compound N=1C=2C(C)=CC(N3CCN(CC3)C(=O)OC(C)(C)C)=CC=2NC=1C(C(NC=C1)=O)=C1NCC(O)C1=CC=CC(Cl)=C1 WDPFLACZLYWILA-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 109
- 239000000243 solution Substances 0.000 description 108
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 30
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 28
- 108091000080 Phosphotransferase Proteins 0.000 description 26
- 102000020233 phosphotransferase Human genes 0.000 description 26
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 24
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012267 brine Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000003818 flash chromatography Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 15
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 14
- 229910021529 ammonia Inorganic materials 0.000 description 14
- 238000000021 kinase assay Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000012417 linear regression Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 6
- GNBKAOHTTIVAMT-UHFFFAOYSA-N 4-iodo-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=CC(I)=C1C=O GNBKAOHTTIVAMT-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 150000001556 benzimidazoles Chemical class 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- NKYNLLWVSLFYOZ-UHFFFAOYSA-N 3-[6-(4-acetylpiperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-4-chloro-1H-pyridin-2-one Chemical compound C1CN(C(=O)C)CCN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3Cl)=O)C2=C1 NKYNLLWVSLFYOZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000005332 alkyl sulfoxy group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 150000002462 imidazolines Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 125000004001 thioalkyl group Chemical group 0.000 description 3
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 3
- RVDCGHYILQGONA-SNVBAGLBSA-N (1s)-2-chloro-1-(7-chloro-1-methyl-2,3-dihydroindol-5-yl)ethanol Chemical compound ClC[C@@H](O)C1=CC(Cl)=C2N(C)CCC2=C1 RVDCGHYILQGONA-SNVBAGLBSA-N 0.000 description 2
- VMKAFJQFKBASMU-KRWDZBQOSA-N (3as)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C([C@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-KRWDZBQOSA-N 0.000 description 2
- HJHMYJMYRHZPEF-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-nitroethanol Chemical compound [O-][N+](=O)CC(O)C1=CC=CC(Cl)=C1 HJHMYJMYRHZPEF-UHFFFAOYSA-N 0.000 description 2
- HYTUDPOPONCSCM-UHFFFAOYSA-N 1-(3-methyl-4-nitrophenyl)imidazole Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2C=NC=C2)=C1 HYTUDPOPONCSCM-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- SLPKYXHBHLTLCD-UHFFFAOYSA-N 1-[4-(3,4-diamino-5-methylphenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC(C)=C(N)C(N)=C1 SLPKYXHBHLTLCD-UHFFFAOYSA-N 0.000 description 2
- IOUSTGPAKJVUGJ-UHFFFAOYSA-N 1-[4-(4-amino-3-methyl-5-nitrophenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC(C)=C(N)C([N+]([O-])=O)=C1 IOUSTGPAKJVUGJ-UHFFFAOYSA-N 0.000 description 2
- ZXTKCOJENNWDTP-UHFFFAOYSA-N 1-[4-[2-(4-iodo-2-methoxypyridin-3-yl)-7-methyl-3h-benzimidazol-5-yl]piperazin-1-yl]ethanone Chemical compound COC1=NC=CC(I)=C1C1=NC2=C(C)C=C(N3CCN(CC3)C(C)=O)C=C2N1 ZXTKCOJENNWDTP-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- ABCHDVQSASAULL-UHFFFAOYSA-N 2-(4,6-dichloropyrimidin-5-yl)-6-imidazol-1-yl-4-methyl-1h-benzimidazole Chemical compound N=1C=2C(C)=CC(N3C=NC=C3)=CC=2NC=1C1=C(Cl)N=CN=C1Cl ABCHDVQSASAULL-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- DMOQUVLZRZWARC-UHFFFAOYSA-N 3-(6-bromo-4-methyl-1H-benzimidazol-2-yl)-4-chloro-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(Br)=CC=2NC=1C1=C(Cl)C=CNC1=O DMOQUVLZRZWARC-UHFFFAOYSA-N 0.000 description 2
- XPTGLFPSVLWIAH-UHFFFAOYSA-N 3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-iodo-1H-pyridin-2-one Chemical compound N=1C=2C(C)=CC(N3C=NC=C3)=CC=2NC=1C1=C(I)C=CNC1=O XPTGLFPSVLWIAH-UHFFFAOYSA-N 0.000 description 2
- NXPFAMCFTFRWLY-NRFANRHFSA-N 3-[6-(4-acetylpiperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-4-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]-1H-pyridin-2-one Chemical compound C1CN(C(=O)C)CCN1C1=CC(C)=C(N=C(N2)C=3C(NC=CC=3N[C@H](CO)CC=3C=CC=CC=3)=O)C2=C1 NXPFAMCFTFRWLY-NRFANRHFSA-N 0.000 description 2
- XQSJHQXYQAUDFC-UHFFFAOYSA-N 4,6-dichloropyrimidine-5-carbaldehyde Chemical compound ClC1=NC=NC(Cl)=C1C=O XQSJHQXYQAUDFC-UHFFFAOYSA-N 0.000 description 2
- VMNUNODKDDCZKW-UHFFFAOYSA-N 4-amino-3-methyl-5-nitrobenzonitrile Chemical compound CC1=CC(C#N)=CC([N+]([O-])=O)=C1N VMNUNODKDDCZKW-UHFFFAOYSA-N 0.000 description 2
- MBZDCUMFFPWLTJ-UHFFFAOYSA-N 4-amino-3-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC=C1N MBZDCUMFFPWLTJ-UHFFFAOYSA-N 0.000 description 2
- ZXFVKFUXKFPUQJ-UHFFFAOYSA-N 4-bromo-2-methyl-6-nitroaniline Chemical compound CC1=CC(Br)=CC([N+]([O-])=O)=C1N ZXFVKFUXKFPUQJ-UHFFFAOYSA-N 0.000 description 2
- UBFFFAXMQZYDAN-UHFFFAOYSA-N 4-chloro-2-methyl-1,3-benzoxazole Chemical compound C1=CC=C2OC(C)=NC2=C1Cl UBFFFAXMQZYDAN-UHFFFAOYSA-N 0.000 description 2
- CIKGNTMCJKDTAN-UHFFFAOYSA-N 4-chloro-3h-1,3-benzoxazol-2-one Chemical compound ClC1=CC=CC2=C1NC(=O)O2 CIKGNTMCJKDTAN-UHFFFAOYSA-N 0.000 description 2
- HNQLDOGYHSKNTN-UHFFFAOYSA-N 4-chloro-6-(2-chloroacetyl)-3h-1,3-benzoxazol-2-one Chemical compound ClCC(=O)C1=CC(Cl)=C2NC(=O)OC2=C1 HNQLDOGYHSKNTN-UHFFFAOYSA-N 0.000 description 2
- FCOXEQRRWIJVOZ-UHFFFAOYSA-N 4-imidazol-1-yl-2-methyl-6-nitroaniline Chemical compound [O-][N+](=O)C1=C(N)C(C)=CC(N2C=NC=C2)=C1 FCOXEQRRWIJVOZ-UHFFFAOYSA-N 0.000 description 2
- XEUDPJHDTZGULF-UHFFFAOYSA-N 4-imidazol-1-yl-2-methylaniline Chemical compound C1=C(N)C(C)=CC(N2C=NC=C2)=C1 XEUDPJHDTZGULF-UHFFFAOYSA-N 0.000 description 2
- UOFSLKHZOPVGHG-UHFFFAOYSA-N 5-bromo-3-methylbenzene-1,2-diamine Chemical compound CC1=CC(Br)=CC(N)=C1N UOFSLKHZOPVGHG-UHFFFAOYSA-N 0.000 description 2
- JRHAXYKFTBEDMV-UHFFFAOYSA-N 5-imidazol-1-yl-3-methylbenzene-1,2-diamine Chemical compound NC1=C(N)C(C)=CC(N2C=NC=C2)=C1 JRHAXYKFTBEDMV-UHFFFAOYSA-N 0.000 description 2
- RFKKTMYPGJBLAW-UHFFFAOYSA-N 6-bromo-2-(4-iodo-2-methoxypyridin-3-yl)-4-methyl-1h-benzimidazole Chemical compound COC1=NC=CC(I)=C1C1=NC2=C(C)C=C(Br)C=C2N1 RFKKTMYPGJBLAW-UHFFFAOYSA-N 0.000 description 2
- MFCFIGKITSBBJL-UHFFFAOYSA-N 6-imidazol-1-yl-2-(4-iodo-2-methoxypyridin-3-yl)-4-methyl-1h-benzimidazole Chemical compound COC1=NC=CC(I)=C1C1=NC2=C(C)C=C(N3C=NC=C3)C=C2N1 MFCFIGKITSBBJL-UHFFFAOYSA-N 0.000 description 2
- PFNSRAOGLJNNLD-UHFFFAOYSA-N 7-chloro-5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClC1=CC(C(=O)CCl)=CC2=C1NC(=O)C2 PFNSRAOGLJNNLD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- STVVMTBJNDTZBF-VIFPVBQESA-N L-phenylalaninol Chemical compound OC[C@@H](N)CC1=CC=CC=C1 STVVMTBJNDTZBF-VIFPVBQESA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- IFTQXEXFRSTUGM-UHFFFAOYSA-N n-(4-imidazol-1-yl-2-methyl-6-nitrophenyl)acetamide Chemical compound C1=C([N+]([O-])=O)C(NC(=O)C)=C(C)C=C1N1C=NC=C1 IFTQXEXFRSTUGM-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000002918 oxazolines Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- YJBKVPRVZAQTPY-UHFFFAOYSA-J tetrachlorostannane;dihydrate Chemical compound O.O.Cl[Sn](Cl)(Cl)Cl YJBKVPRVZAQTPY-UHFFFAOYSA-J 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 150000003549 thiazolines Chemical class 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000006168 tricyclic group Chemical group 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- KOSUZOTZIAPVKN-QMMMGPOBSA-N (1S)-2,2-diamino-1-(7-bromo-2,3-dihydro-1-benzofuran-5-yl)ethanol Chemical compound BrC1=CC([C@H](O)C(N)N)=CC2=C1OCC2 KOSUZOTZIAPVKN-QMMMGPOBSA-N 0.000 description 1
- XZLVHSPOHDJNMQ-MRVPVSSYSA-N (1s)-1-(3-bromo-4-methoxyphenyl)-2-chloroethanol Chemical compound COC1=CC=C([C@H](O)CCl)C=C1Br XZLVHSPOHDJNMQ-MRVPVSSYSA-N 0.000 description 1
- MNEMOYMUJXAGNE-DDWIOCJRSA-N (1s)-2-amino-1-(3-chloro-4-methoxyphenyl)ethanol;hydrochloride Chemical compound Cl.COC1=CC=C([C@H](O)CN)C=C1Cl MNEMOYMUJXAGNE-DDWIOCJRSA-N 0.000 description 1
- HDXPPVNAHRADDH-DDWIOCJRSA-N (1s)-2-amino-1-(3-chloro-4-methylsulfanylphenyl)ethanol;hydrochloride Chemical compound Cl.CSC1=CC=C([C@H](O)CN)C=C1Cl HDXPPVNAHRADDH-DDWIOCJRSA-N 0.000 description 1
- UPJMEEMDJVVXRP-DDWIOCJRSA-N (1s)-2-amino-1-(4-chloro-2-methyl-1,3-benzoxazol-6-yl)ethanol;hydrochloride Chemical group Cl.C1=C([C@H](O)CN)C=C2OC(C)=NC2=C1Cl UPJMEEMDJVVXRP-DDWIOCJRSA-N 0.000 description 1
- QXNGSOXIIWEFAO-HNCPQSOCSA-N (1s)-2-amino-1-(7-chloro-1-methyl-2,3-dihydroindol-5-yl)ethanol;hydrochloride Chemical compound Cl.NC[C@@H](O)C1=CC(Cl)=C2N(C)CCC2=C1 QXNGSOXIIWEFAO-HNCPQSOCSA-N 0.000 description 1
- SWAAZPOQASGLIS-HNCPQSOCSA-N (1s)-2-amino-1-(7-chloro-1-methylindol-5-yl)ethanol;hydrochloride Chemical compound Cl.NC[C@@H](O)C1=CC(Cl)=C2N(C)C=CC2=C1 SWAAZPOQASGLIS-HNCPQSOCSA-N 0.000 description 1
- QOSKETZIPGIXHN-MRVPVSSYSA-N (1s)-2-chloro-1-(4-chloro-2-methyl-1,3-benzoxazol-6-yl)ethanol Chemical compound C1=C([C@H](O)CCl)C=C2OC(C)=NC2=C1Cl QOSKETZIPGIXHN-MRVPVSSYSA-N 0.000 description 1
- UVLODALMANQJQZ-SNVBAGLBSA-N (1s)-2-chloro-1-(7-chloro-1-methylindol-5-yl)ethanol Chemical compound ClC[C@@H](O)C1=CC(Cl)=C2N(C)C=CC2=C1 UVLODALMANQJQZ-SNVBAGLBSA-N 0.000 description 1
- RRMCWFHKHSBXJH-VIFPVBQESA-N (2s)-2-amino-3-(3-bromophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=CC(Br)=C1 RRMCWFHKHSBXJH-VIFPVBQESA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- OQCFWECOQNPQCG-UHFFFAOYSA-N 1,3,4,8-tetrahydropyrimido[4,5-c]oxazin-7-one Chemical compound C1CONC2=C1C=NC(=O)N2 OQCFWECOQNPQCG-UHFFFAOYSA-N 0.000 description 1
- PWRFDGYYJWQIAB-UHFFFAOYSA-N 1,3,5-trifluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=C(F)C=C1F PWRFDGYYJWQIAB-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- HSZHWAOGQOXSSM-UHFFFAOYSA-N 2-(3,5-difluoro-2-nitrophenyl)propanedioic acid Chemical compound OC(=O)C(C(O)=O)C1=CC(F)=CC(F)=C1[N+]([O-])=O HSZHWAOGQOXSSM-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- PMFZBFPJVNDTRJ-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-2-chloro-1-phenylethanone Chemical compound C1=C(Br)C(OC)=CC=C1C(Cl)C(=O)C1=CC=CC=C1 PMFZBFPJVNDTRJ-UHFFFAOYSA-N 0.000 description 1
- AMFABIDXRCKLRE-UHFFFAOYSA-N 2-(4-iodo-2-methoxypyridin-3-yl)-7-methyl-3h-benzimidazole-5-carbonitrile Chemical compound COC1=NC=CC(I)=C1C1=NC2=C(C)C=C(C#N)C=C2N1 AMFABIDXRCKLRE-UHFFFAOYSA-N 0.000 description 1
- XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- KXZXJEVYBOPMLC-UHFFFAOYSA-N 2-chloro-1-(4-chloro-2-methyl-1,3-benzoxazol-6-yl)ethanone Chemical compound C1=C(C(=O)CCl)C=C2OC(C)=NC2=C1Cl KXZXJEVYBOPMLC-UHFFFAOYSA-N 0.000 description 1
- SCZJVSVJAILREE-UHFFFAOYSA-N 2-chloro-1-(7-chloro-1-methyl-2,3-dihydroindol-5-yl)ethanone Chemical compound ClCC(=O)C1=CC(Cl)=C2N(C)CCC2=C1 SCZJVSVJAILREE-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- VRGCYEIGVVTZCC-UHFFFAOYSA-N 3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione Chemical compound ClC1=C(Cl)C(=O)C(=O)C(Cl)=C1Cl VRGCYEIGVVTZCC-UHFFFAOYSA-N 0.000 description 1
- RENQQMGYOXDBQA-UHFFFAOYSA-N 3,4-diamino-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC(N)=C1N RENQQMGYOXDBQA-UHFFFAOYSA-N 0.000 description 1
- VMCYKRLUYHGDDI-UMSFTDKQSA-N 3-(6-bromo-4-methyl-1H-benzimidazol-2-yl)-4-[[(2S)-1-phenyl-3-trityloxypropan-2-yl]amino]-1H-pyridin-2-one Chemical compound C([C@@H](NC1=C(C(NC=C1)=O)C=1NC=2C=C(Br)C=C(C=2N=1)C)CC=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VMCYKRLUYHGDDI-UMSFTDKQSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- IHVNKSXTJZNBQA-UHFFFAOYSA-N 3-methyl-4-nitrobenzonitrile Chemical compound CC1=CC(C#N)=CC=C1[N+]([O-])=O IHVNKSXTJZNBQA-UHFFFAOYSA-N 0.000 description 1
- DJVGGCMBSOTOSR-ZCFIWIBFSA-N 4-chloro-6-[(1s)-2-chloro-1-hydroxyethyl]-3h-1,3-benzoxazol-2-one Chemical compound ClC[C@@H](O)C1=CC(Cl)=C2NC(=O)OC2=C1 DJVGGCMBSOTOSR-ZCFIWIBFSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- LJMXTWXGOCCHQO-UHFFFAOYSA-N 4-hydroxy-6-oxo-1H-pyrimidine-5-carbaldehyde Chemical compound OC1=NC=NC(O)=C1C=O LJMXTWXGOCCHQO-UHFFFAOYSA-N 0.000 description 1
- UMWNJKXMTCSXPG-DDWIOCJRSA-N 5-[(1s)-2-amino-1-hydroxyethyl]-7-chloro-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.ClC1=CC([C@H](O)CN)=CC2=C1NC(=O)C2 UMWNJKXMTCSXPG-DDWIOCJRSA-N 0.000 description 1
- GRVCMTABBYJKTD-UHFFFAOYSA-N 5-fluoro-3-methyl-2-nitroaniline Chemical compound CC1=CC(F)=CC(N)=C1[N+]([O-])=O GRVCMTABBYJKTD-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- FPDLUAACCNVSQA-UHFFFAOYSA-N 7-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=CC2=C1NC(=O)C2 FPDLUAACCNVSQA-UHFFFAOYSA-N 0.000 description 1
- HMYNJUJZRRBRLB-UHFFFAOYSA-N 7-chloro-1-methyl-2,3-dihydroindole Chemical compound C1=CC(Cl)=C2N(C)CCC2=C1 HMYNJUJZRRBRLB-UHFFFAOYSA-N 0.000 description 1
- OMPUMOUPCGQKNM-UHFFFAOYSA-N 7-chloro-2,3-dihydro-1h-indole Chemical compound ClC1=CC=CC2=C1NCC2 OMPUMOUPCGQKNM-UHFFFAOYSA-N 0.000 description 1
- SMWDZVYYODVBGU-MRVPVSSYSA-N 7-chloro-5-[(1s)-2-chloro-1-hydroxyethyl]indol-2-one Chemical compound C1=C([C@@H](CCl)O)C=C(Cl)C2=NC(=O)C=C21 SMWDZVYYODVBGU-MRVPVSSYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 235000007849 Lepidium sativum Nutrition 0.000 description 1
- 244000211187 Lepidium sativum Species 0.000 description 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100026379 Neurofibromin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101500028887 Rattus norvegicus Neuromedin N Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- KSBZFAQREVCNIH-UHFFFAOYSA-N [1-(3-chlorophenyl)-2-nitroethoxy]-triethylsilane Chemical compound CC[Si](CC)(CC)OC(C[N+]([O-])=O)C1=CC=CC(Cl)=C1 KSBZFAQREVCNIH-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000005365 aminothiol group Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- CIPMQPTWGWCBLF-UHFFFAOYSA-N chembl382387 Chemical compound C=1C(CC(=O)O)=CC(C=2NC3=CC=CC=C3N=2)=C(O)C=1C1=CC=CC([N+]([O-])=O)=C1 CIPMQPTWGWCBLF-UHFFFAOYSA-N 0.000 description 1
- HHYOQRDAWFAMAJ-INIZCTEOSA-N chembl397667 Chemical compound C([C@@H](CO)NC1=C(C(NC=C1)=O)C=1NC=2C=C(Br)C=C(C=2N=1)C)C1=CC=CC=C1 HHYOQRDAWFAMAJ-INIZCTEOSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000012602 chemosensitivity assay Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PFOJBYJEHUXUMR-UHFFFAOYSA-N ditert-butyl 2-(3,5-difluoro-2-nitrophenyl)propanedioate Chemical compound CC(C)(C)OC(=O)C(C(=O)OC(C)(C)C)C1=CC(F)=CC(F)=C1[N+]([O-])=O PFOJBYJEHUXUMR-UHFFFAOYSA-N 0.000 description 1
- BPKIDOZPXURPKQ-UHFFFAOYSA-N ditert-butyl 2-(3-amino-5-fluoro-2-nitrophenyl)propanedioate Chemical compound CC(C)(C)OC(=O)C(C(=O)OC(C)(C)C)C1=CC(F)=CC(N)=C1[N+]([O-])=O BPKIDOZPXURPKQ-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004050 homopiperazines Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GEGPEDZKUUFDDR-UHFFFAOYSA-N n-(4-cyano-2-methyl-6-nitrophenyl)-2,2,2-trifluoroacetamide Chemical compound CC1=CC(C#N)=CC([N+]([O-])=O)=C1NC(=O)C(F)(F)F GEGPEDZKUUFDDR-UHFFFAOYSA-N 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Substances CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
NOVEL TYROSINE KINASE INHIBITORS
This application claims the benefit under 35 U.S.C. Section 119(e) of U.S.
Provisional Patent Application No. 60/279,327 filed March 28, 2001.
The present invention relates generally to the field of tyrosine kinase enzyme inhibition using novel small molecules.
Tyrosine Kinases are a class of enzymes, which catalyze the transfer of the terminal phosphate of adenosine triphosphate to the phenolic hydroxyl group of a tyrosine residue present in the target protein. Tyrosine kinases play a critical role in signal transduction for several cellular functions including cell proliferation, carcinogenesis, apoptosis, and cell differentiation (Plowman, G. D.; Ullrich, A;
Shawver, L. K.: Receptor Tyrosine Kinases As Targets For Drug Intervention.
DN&P (1994) 7: 334-339). Therefore inhibitors of these enzymes would be useful for the treatment or prevention of proliferative diseases which are dependent on these enzymes. Strong epidemiologic evidence suggests that the overexpression or activation of receptor protein tyrosine kinases leading to constitutive mitogenic signaling is an important factor in a growing number of human malignancies.
Tyrosine kinases that have been implicated in these processes include Abl, CDK’s,
EGF, EMT, FGF, FAK, Flk-1/KDR, HER-2, IGF-1R, IR, LCK, MET, PDGF, Src, and VEGF (Traxler, P.M. Protein Tyrosine Kinase Inhibitors in Cancer Treatment.
Exp. Opin. Ther. Patents (1997) 7: 571-588; incorporated herein by reference).
Hence, there is an ongoing need to investigate novel compounds that can be used to regulate or inhibit tyrosine kinase enzymes.
’ The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using inhibitors of tyrosine kinase enzymes to treat diseases which are characterized by an overexpression or upregulation of tyrosine kinase activity such as cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases and immunologic disorders (Powis, G.; Workman, P. Signaling targets For The }
Development of Cancer Drugs. Anti-Cancer Drug Design (1994), 9: 263-277;
Merenmies, J.; Parada, L. F.; Henkemeyer, M. Receptor Tyrosine Kinase Signaling in Vascular Development. Cell Growth Differ (1997) 8: 3-10; Shawver, L. K ;
Lipsosn, K. E.; Fong, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M.
Receptor Tyrosine Kinases As Targets For Inhibition of Angiogenesis. Drug
Discovery Today (1997) 2: 50-63; all herein incorporated by reference).
In addition to being used as single agents, it is contemplated that tyrosine kinase inhibitors can enhance the activity of cytotoxic or cytostatic treatments when used in combination with standard therapies known in the art.
The present invention is directed to compounds having formula I
R” R'y Rg
R’ N Ww
Rr N X,
RS R® AR’
I its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and solvates thereof; wherein
X is selected from the group consisting of N, C, C;-Cs alkyl, C;-C; alkyl substituted with one or more R’ and a direct bond; .
Y is selected from the group consisting of O and S ;
W is selected from the group consisting of N, C, O, and S, provided that when .
Wis Oor S, R’ is absent;
R',R% RY, R* R’ RS R’, R® R® are each independently selected from the group consisting of H, Cy alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, OR, NO,, OH, SR%, NR®R®' , CN, CO,R*’, CONR®R®', CO,NR*R®' ’ NR®CONR®R® NR®’SO,R®' , SO,NRPR®', C(NRZ))NR®R®', aryl, heteroaryl, i 5 (CH2)WOR®, (CH,),NR®R®, (CH,),SR®, (CH), aryl, (CHa), heteroaryl, , (CHa), heterocycloalkyl, NH-Z-aryl, and NH-Z-heteroaryl; wherein n is 1 to 3; and
Z is selected from the group consisting of C; — C4 alkyl, alkenyl, and alkynyl chain; Z having one or more hydroxy, thiol, alkoxy, thioalkoxy, amino, halo,
NR¥SO,R® groups; Z optionally incorporating one or more groups selected from the group consisting of CO, CNOH, CNOR®’, CNNR® , CNNCOR® and CNNSO,R*" and
R®, R®, and R®? are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, and alkyl-R® wherein
R® is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, -
NR¥*COOR?, -NR*C(0)R*, -NR**SO,R?, -C(O)NR*R?', heteroaryl or heterocycloalkyl; and
R*® and R* are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R? .
In preferred embodiments, R!, R’, R%and R® are H;
R? and R*are H or F;
Y is O;
X is selected from the group consisting of N and CH;
Wis N;
R’ is selected from the group consisting of H, methyl, ethyl, isopropyl, secondary butyl, cyclopropyl, F, and CF3; » RS is selected from the group consisting of H, 2-aminomethylpyridine,
NHCH(CH>OH)CH;Ph, NHCH,CH(OH)aryl, and NHCH(CH,OH)CH,aryl; and
R® is selected from the group consisting of OR®, C(NH)NHR®, C(O)NHR®° imidazole, imidazoline, tetrahydropyrimidine, piperazine, morpholine, homomorpholine, piperidine, pyrrolidine, homopiperazine and amino; wherein
R% is sclected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, and alkyl-R® wherein R” is hydrogen, alkenyl, hydroxy, thiol, . thioalkoxy, alkoxy, thioalkoxy, halo, cyano, sulfoxy, sulfonyl, -NR**COOR?!, -
NRPC(O)R*, -NR*SO,R*, -C(O)NR*R™, or a heteroaryl or heterocycloalkyl; and
R30 and Rs; are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R* .
The invention also provides a pharmaceutical composition comprising a compound of formula I, as defined above, and a pharmaceutically acceptable carrier.
The invention further provides a pharmaceutical composition comprising a compound of formula I, as defined above, in combination with pharmaceutically acceptable carrier and at least one other anti-cancer agent optionally formulated as a fixed dose.
Additionally provided is a method of treating a condition associated with at least one tyrosine kinase enzyme comprising administering to a mammalian species in need of such trcatment an effective amount of a compound of formula I, as defined above. Furthermore, the invention provides a method of treating a condition associated with at least one tyrosine kinase enzyme comprising administering to a mammalian species at least one other anti-cancer agent in combination with a compound of formula I, as defined above.
The present invention provides for compounds of formula I, as defined above, pharmaceutical compositions employing such compounds and methods of using such compounds.
Listed below are definitions of various terms used to describe the compounds of the instant invention. These definitions apply to the terms as they are used * throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group.
The term "alkyl" herein alone or as part of another group refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 12 carbon atoms unless otherwise defined. An alkyl group is an optionally substituted straight, ) branched or cyclic saturated hydrocarbon group. When substituted, alkyl groups may . 5 be substituted with up to four substituent groups, R as defined, at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with “branched alkyl group”. Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, 10 undecyl, dodecyl, and the like. Exemplary substituents may include but are not limited to one or more of the following groups: hydroxy, halo (such as F, Cl, Br, I), haloalkyl (such as CCl3 or CF3), alkoxy, alkylthio, cyano, carboxy (-COOH), alkylcarbonyl (-C(O)R), alkoxycarbonyl (-OCOR), amino, carbamoyl (-NHCOOR or -OCONHR), urea (-NHCONHR), thiol, (-SH), sulfoxy, sulfonyl, aryl, heteroaryl, and 15 heterocycloalkyl. Alkyl groups as defined may also comprise one or more carbon to carbon double bonds or one or more carbon to carbon triple bonds. Alkyl groups may also be represented by the formula alkyl-R*. In preferred embodiments, the alkyl group is a methyl, ethyl, propyl or butyl group and include substituted methyl, ethyl, propyl! or butyl groups. 20 The term “alkenyl” herein alone or as part of another group refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon double bond. An alkenyl group may be optionally substituted in the same manner as described for an alkyl group.
The term “alkynyl” herein alone or as part of another group refers to a 25 hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond. An alkynyl group may be optionally substituted in the same manner as described for an alkyl group.
The term "alkoxy" as used alone or in combination herein refers to a straight v or branched chain alkyl group covalently bonded to the parent molecule through an 30 oxygen atom linkage containing from one to ten carbon atoms and the terms "C,.¢ ) alkoxy" and "lower alkoxy" refer to such groups containing from one to six carbon atoms, examples include, but are not limited to, methoxy, ethoxy, propoxy,
WG 02/079192 PCT/USG2/09402 1SOpropoxy, butoxy, t-butoxy and the like. The term "optionally substituted" when used in connection with an alkoxy substituent refers to the replacement of up to two hydrogens, preferably on different carbon atoms with a radical selected form the group of lower alkyl, phenyl, cyano, halo, trifluoromethyl, nitro, hydroxy, alkanoyl, ) amino, monoalkyl amino and dialkylamino. Alkoxy groups may be substituted in the i same manner that alkyl groups can be substituted as described above.
The term “sulfoxy” herein alone or as part of a group refers to -SO and may be substituted with, for example, alkyl or aryl groups.
The term “sulfonyl” herein alone or as part of a group refers to ~SO, and may be substituted with alkyl or aryl groups.
The term "amino" herein alone or as part of another group refers to -NH;. An "amino" may optionally be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, alkenyl, alkynyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. Preferred substituents include alkylamino and dialkylamino, such as methylamino, ethylamino, dimethylamino, and diethylamino. These substituents may be further substituted with a carboxylic acid or any of the alkyl or aryl substituents set out herein. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1- pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 4- sulfoxymorpholine, 4-sulfonylmorpholine, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4- arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl , 1-homopiperazinyl, 4-alkyl-1- homopiperazinyl, 4-arylalkyl-1-homopiperazinyl, 4-diarylalkyl-1-homopiperazinyl; 1- pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy .
The term "aryl" herein alone or as part of another group refers to monocyclic or bicyclic aromatic rings, e.g. phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., napthyl, phenanthrenyl and the like. An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being : present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms. Aryl groups may optionally be substituted with one or more groups including, but not limited to halogen, alkyi,
alkenyl, alkynyl, alkoxy, hydroxy, carboxy, carbamoyl, alkyloxycarbonyl, alkylaminocarbonyl, nitro, trifluoromethyl, amino, cycloalkyl, cyano, alkyl S(O),, (m=0, 1, 2), or thiol. Aryl groups may also be substituted with heterocycloalkyl and ’ heterocycloaryl groups to form fused rings, such as dihydrobenzfuranyl, oxindolyl, . 5 indolyl, indolinyl, oxindolyl, benzoxazolidinonyl, benzoxazolinyl and benzoxazolidinone.
The term “cycloalkyl!” herein alone or as part of another group refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms. Further, a cycloalkyl may be substituted. A substituted cycloalkyl refers to such rings having one, two, or three substituents, preferably one, selected from the group consisting of halo, alkyl, substituted alkyl, alkenyl, alkynyl, nitro, cyano, oxo (=O), hydroxy, alkoxy, thioalkyl, -CO,H, -OC(=0)H, CO,-alkyl, -
OC(=0)alkyl, =N-OH, =N-O-alkyl, aryl, heteroaryl, heterocyclo, a five or six membered ketal (i.e. 1,3-dioxolane or 1,3-dioxane), -NR’R”, -C(=O)NR’'R”, —
OC(=O)NR’R”’, -NR’CO,’R”, -NR’C(=0)R”, -SO,NR’R”, and -NR’SO,’R”, wherein each of R’ and R” is independently selected from hydrogen, alkyl, substituted alkyl, and cycloalkyl, or R’ and R” together form a heterocyclo or heteroaryl ring.
Cycloalkyl groups may also be substituted with hetero atoms such as O, N, and S to form heterocycloalkyl groups. Preferred heterocycloalkyl groups include optionally substituted morpholine, homomorpholine (7 membered ring), thiomorpholine, piperazine, homopiperazine (7 membered ring), and piperidine.
The term “heteroaryl” herein alone or as part of another group refers to substituted and unsubstituted aromatic S or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. > The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and ’ sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non- aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may contain zero, one, two or three substituents selected from the group consisting of halo, alkyl, substituted alkyl, ) alkenyl, alkynyl, nitro, cyano, hydroxy, alkoxy, thioalkyl, -CO,H, -OC(=O)H, -CO»- alkyl, -OC(=0O)alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, substituted cycloalkyl, heterocyclo, heteroaryl, -NR’R”, -C(=O)NR’R”, —
OC(=O)NR’R’’, -NR’CO;’R”, -NR’C(=O)R”, -SO,NR’R”, and -NR’SO,R”, wherein each of R” and R” is independently selected from hydrogen, alkyl, substituted alkyl, and cycloalkyl, or R’ and R” together form a heterocyclo or heteroaryl ring.
Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrrolidinyl, imidazolinyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and the like.
Exemplary bicyclic heteroaryl groups include indolyl, indolinyl, oxindolyl, benzoxazolidinone, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
Exemplary tricyclic heteroaryl groups include carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
The term "halogen" or "halo" herein alone or as part of another group refers to chlorine, bromine, fluorine or iodine selected on an independent basis.
The term "hydroxy" herein alone or as part of another group refers to -OH.
The term "thioalkoxy" herein alone or as part of another group refers to an alkyl group as defined herein attached to the parent molecular group through a sulfur atom. Examples of thioalkoxy include, but are not limited to, thiomethoxy, thioethoxy, and the like. *
Abbreviations: “Ph” represents phenyl; “Me” represents methyl; and “Et” represents ethyl.
An “anti-cancer agent” as used herein includes known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; ’ topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as . 5 CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; anti-metabolites, such as methotrexate; tyrosine kinase inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; Her1/2 inhibitors and monoclonal antibodies directed against growth factor receptors such as erbitux (EGF) and herceptin (Her2).
When a functional group is termed “protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site. Suitable protecting groups for the compounds of the present invention will be recognized from the present application taking into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al., Protective Groups in
Organic Synthesis, Wiley, N.Y. (1991).
When C,¢alkyl, alkenyl, alkynyl, cycloalkyl are substituted, they are preferably substituted with one or more hydroxy, cyano, carbamoyl, hydroxy, alkoxy, thiol, alkenyl, thioalkoxy, amino, alkylamino, amido, sulfonyl, sulfoxy, sulfonamido, halo, heterocycloalkyl, aryl or heteroaryl.
When aryl or heteroaryl are substituted, they are preferably substituted with one or more alkyl, alkenyl, alkynyl, cyano, carbamoyl, hydroxy, alkoxy, thioalkoxy, amino, amido, sulfonamido, halo or with R’, R>* wherein R’, R’’ form a ring that is fused to the aryl group. When CHoaryl or heteroaryl are substituted, they are preferably substituted with one or more alkyl, alkyenyl, alkynyl, cyano, carbamoyl, hydroxy, alkoxy, thioalkoxy, amino, amido, sulfonamido, or halogen.
When NH-Z-aryl or NH-Z-heteroaryl groups are substituted, they are . preferably substituted with one or more alkyl, alkenyl, alkynyl, hydroxy, alkoxy, - thioalkoxy, amino, halogen, nitro, nitrile, carboxylate, alkoxycarbonyl, carbamoyl, ester, amide, aryl, or heteroaryl ’ The numbers in the subscript after the symbol "C" define the number of carbon atoms a particular group can contain. For example "C|_g alkyl" means a straight or branched saturated carbon chain having from one to six carbon atoms; examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t- butyl, n-pentyl, sec-pentyl, isopentyl, and n-hexyl. Depending on the context, "Cj _g alkyl” can also refer to Cj _g alkylene which bridges two groups; examples include propane-1,3-diyl, butane-1,4-diyl, 2-methyl-butane-1,4-diyl, etc. "Co _g alkenyl" . means a straight or branched carbon chain having at least one carbon-carbon double bond, and having from two to six carbon atoms; examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl. Depending on the context, "Cp. alkenyl" can also refer to Cy_g alkenediyl which bridges two groups; examples include ethylene-1,2-diyl (vinylene), 2-methyl-2-butene-1,4-diyl, 2-hexene-1,6-diyl, etc. "Cp.g alkynyl" means a straight or branched carbon chain having at least one carbon-carbon triple bond, and from two to six carbon atoms; examples include cthynyl, propynyl, butynyl, and hexynyl.
The term “alkyl-R® ” includes optionally substituted alkyl groups such as methyl, ethyl, propyl, and butyl, attached to an R>group. R> generally includes hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, -NHCOOH, -NHC(O)-, -NHSO;-, -C(O)NH,, heteroaryl or heterocycloalkyl groups such as morpholinyl or group having the formula: 0] Oo N
Nee EE Ee
Nay N N Rat NN p Jo i” “ ~<A, oh, CY of —Ul
The terms “imidazole” and “imidazoline” herein alone or as part of another group includes substituted imidazoles and substituted imidazolines. Similarly, the term “tetrahydropyrimidine” includes substituted tetrahydropyrimidines. Likewise, h the terms “piperazine”, “piperidine” “morpholines”, “homopiperazines”, “homomorpholines” and “pyrrolidine” include substituted piperazines, substituted piperidines, substituted morpholines, substituted homomorpholines and substituted pyrrolidines, respectively.
Compounds of the present invention have the general formula I:
R= R'y Rg
RA AN Se
Resast
LE R® WR’ its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and solvates thereof; wherein
X is selected from the group consisting of N, C, C,-C; alkyl, C,-C; alkyl substituted with one or more R’ and a direct bond;
Y is selected from the group consisting of O and S ;
W is selected from the group consisting of N, C, O, and S, provided that when
Wis OorS,R’is absent;
R!, R% R’, RY, R® R%, R", R®, R® are each independently selected from the group consisting of H, Cj. alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, OR®, NO,, OH, SR¥®, NR¥R®', CN, CO,R®, CONR®R®, CO,NR*R®! ,
NR®2CONR®R®', NR¥SO,R®' , SO,NR®R®', C(NR®*)NR®R®' aryl, heteroaryl, (CH2).OR®’, (CH2),NR*’R®, (CH,),SR%, (CH,), aryl, (CH), heteroaryl, , (CH2)n heterocycloalkyl, NH-Z-aryl, and NH-Z-heteroaryl, wherein n is 1 to 3; and
Z is selected from the group consisting of C; — C4 alkyl, alkenyl, and alkynyl chain; Z having one or more hydroxy, thiol, alkoxy, thioalkoxy, amino, halo,
NR*’SO;R® groups; Z optionally incorporating one or more groups selected from the . group consisting of CO, CNOH, CNOR®®, CNNR®, CNNCOR® and CNNSO,R®* and i R%, and R* are independently selected from the group consisting of H, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, and alkyl-R* wherein
R? is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, - : ’
NR¥*COOR?Y, -NR*C(O)R*, -NR¥SO,R*, -C(O)NRR*, heteroaryl or heterocycloalkyl; and
R* and R*' are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%.
In some embodiments of the present invention, R?is —OR%. R® is alkyl, or — alkyl-R%, wherein R* is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano, alkylsulfoxy, alkylsulfonyl, -R3*COOR*, -NR¥*C(O)R?', -
NR*SO,R? t -C(O)NRR¥, heteroaryl or heterocycloalkyl; and R3p and Rj, are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%. In preferred embodiments,
R% is methyl, -(CH,),CH,OH, or -(CH;),CH,N(CH,CH,),0, and nis 0, 1, or 2.
In some embodiments, R® is piperazine, homopiperazine, 3-methylpiperazine, or 3,5-dimethylpiperazine being optionally substituted at the 4-N position with a compound selected from the group consisting of alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, alkyl-R*, -C(O)-R'>, or -CO,R'® wherein R"’ is hydrogen, alkyl, aryl, alkyl-R%” , amino or aryl; and RZ is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, cyano, halo, sulfoxy, sulfonyl, arylsulfonyl, -NR**COOR*, -NR*C(O)R?*!, -NR*SO,R*', -C(O)NRR*', heteroaryl or heterocycloalkyl and R* and R*' are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%. In preferred embodiments, piperazine is substituted with Me,
CHcyclopropyl, CH,CH,NMe,, CH,CH,NEt,, CH,CH,NH,, CH,CH;NHMe,
CH,CH;NHEt, N-CH,CH,N(CH,CH,),0, (CH,),CH;-R,s wherein R® is OH, OMe,
F, CN, CF;, SOCHj or SO,CH3 whereinnis 0, 1, or 2.
In some embodiments, R* is an amino group. Preferred amino groups include
NHCH,CH,0OH, NMeCH,CH,0OH, NEtCH,CH,OH, NHCH,CH,NH,,
NMeCH,CH,NH,, NEtCH,CH,NH,, NHCH,CH,;NMe,, NMeCH,CH;NMe,,
NEtCH,CH;NMe,, NHCH,CH,NEt;, NMeCH,CH,;NEt,, NEtCH,CH,NEt,, -
NHCH,CH,N(CH,CH,),0, NMeCH,;CH,;N(CH,CH,),0, NEtCH,CH,;N(CH,CH;),0.
In some embodiments, R? is an optionally substitued piperidine. Preferred substituents are selected from the group consisting of hydroxy, thiol, amino,
alkylamino, dialkylamino, alkoxy, thioalkoxy, 1,3 dioxolane (-OCHR"),, 1,3 dioxane (-OCHR'"’CHR"CHR"0-) -NHC(O)R 3, -NHCO,R"*, wherein R" is hydrogen, alkyl or alkyl-R* wherein R% is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano, alkylsulfoxy, alkylsulfonyl, -NR**COOR?', -NR*C(O)R?', - NR™SO,R*, -C(O)NR*R*, heteroaryl or heterocycloalkyl; and R* and R*' are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%.
In some embodiments R® is an optionally substituted morpholine, homomorpholine, thiomorpholine, sulfoxymorpholine, or sulfonylmorpholine.
Preferred substituents include hydroxy, thiol, amino, alk ylamino, dialkylamino, alkoxy, thioalkoxy, alkyl-R* -NHC(O)R'?, -NHCO,R"’, wherein R"’ is hydrogen, alkyl or alkyl-R% wherein R” is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano, alkylsulfoxy, alkylsulfonyl, -NR*COOR?!, -
NR*’C(O)R?*, -NR*sO,R*!, -C(O)NRR¥, heteroaryl or heterocycloalkyl; and R¥® and RY are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R”.
In some embodiments, R* is a pyrrolidine. Preferred pyrrolidines include, 3- hydroxyl pyrrolidine, 3- alkoxy pyrrolidine, and 3-alkylamino pyrrolidine.
According to one embodiment of the present invention, R? is an optionally substituted N-tetrahydropyrimidine or N-imidazoline wherein the substituents are, preferably, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cyanoalkyl, carboxyl, or carboxamide.
In some embodiments, R® is is selected from the group consisting of H, 2- aminomethylpyridine, NHCH,CH(OH)aryl, and NHCH(CH,OH)CHaaryl, wherein the aryl group is optionally substituted. In preferred embodiments, the aryl group is substituted with Br, Cl, F, or methoxy. In some embodiments, RS has one of the following formulae:
“nu “SNH NH
HO HO HO
Ryy Riz Ry7 ! 0 \ NRgq NRgp 0 “NH pe
FN SNH :
HO Ho
HO
OR
0 Riz R
NR NR 7 0 Riz d 0 \=N wherein R* is hydrogen or alkyl, preferably methyl, and R'7 is hydrogen or halogen, such as Br, Cl or F.
Preferred compounds of the present invention have one of the following formulae:
Biz Pi xX
Rs N ge N ) NH ro N ) NH [Sen Co
HN HN
: HOw HO" n Aur fw Fr “ Rye Pig Ryg Ris
I
Foon Qo Ae
AM N 3 NH oon lo}
CL 7 RN N NH
HN [Sen . HOw H
HOw wv . Ruy v
Ris Rig No
Ris Ryg
A n uo N o
T iQ n Q NH 0 | N NH [See In
N HN
HN
HOw HOw
Ry Riz vi of, Fi ae vi Ris Rig
Rys De:
Fis @ N 2 NH Rig 4@! N B NH
CL [Sen
HN HN
OR
HOw HOw 0 0 vill 1X
Rio Ria Rig Rs wherein
R'? and R" are, independently, hydrogen, alkyl, or alkyl-R>;
R'is hydrogen, alkyl, or alkyl-R%;
R'®is independently, hydrogen or methyl;
R", R"® and R" are, independently, hydrogen, halogen, or alkoxy,or R'® and p R" together form a heterocycloalkyl or heteroaryl group;
R¥ is hydrogen, hydroxy, thiol, alkenyl, alkoxy, thioalkoxy, amino, halo, : cyano, sulfoxy, sulfonyl, -NR*®*COOR?!, -NR*C(O)R?!, -NR*’SO,R¥, -
C(O)NR*R? heteroaryl or heterocycloalkyl; and
R*® and R* are, independently, hydrogen, alkyl, cycloalkyl or alkyl-R%.
In preferred embodiments, R'? is hydrogen, methyl, hydroxymethyl, methoxymethyl, CHF, CH>CN, CO,H, or —CONR*R* wherein R* and R>' are, independently, hydrogen, or alkyl-R*>;
R "is H;
R'is Br,Clor F;
R'% is halo or methoxy; and
R" is H.
Suitable examples of salts of the compounds according to the invention include inorganic or organic acids. These include, but are not limited to, hydrochloride, hydrobromide, sulfate, methanesulfonate, maleate, fumarate, phosphate and other pharmaceutically acceptable salts. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of formula I or their pharmaceutically acceptable salts, are also included.
All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The definition of the compounds according to the invention embraces all possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates by conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
It should be understood that the present invention includes prodrug forms of the compounds of formula I. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see: (a) Design of Prodrugs, edited by H. Bundgaard (Elsevier, 1985); and Methods in
Enzymology, Vol. 42, pp. 309-396, edited by K. '
Widder et al., (Academic Press, 1985); (b) A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. )
Bundgaard, Chapter 5, "Design and
Application of Prodrugs,” by H. Bundgaard, pp. 113-191 (1991); (c) H. Bundgaard, Advanced Drug Deliver Reviews, 8, pp. 1-38 (1992); (d) H. Bundgaard et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and (e) N. Kayeka et al., Chem. Phar. Bull, 32, 692 (1984). x 5 The invention also provides a pharmaceutical composition comprising a compound of formula I, as defined above, and a pharmaceutically acceptable carrier and at least one other anti-cancer agent formulated as a fixed dose. Preferred anti- cancer agents are selected from the group consisting of: tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate, anastrozole, letrazole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, goserelin acetate, luprolide, finasteride, herceptin, methotrexate, S-fluorouracil, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotephan, vincristine, taxol, taxotere, etoposide, teniposide, amsacrine, irinotecan, topotecan, an epothilone; a tyrosine kinase inhibitor such as Iressa or OSI-774; an angiogenesis inhibitor; an EGF inhibitor; a VEGF inhibitor; a CDK inhibitor; a Herl/2 inhibitor and monoclonal antibodies directed against growth factor receptors such as erbitux (EGF) and herceptin (Her2).
The invention further provides a method of treating a condition via modulation of at least one tyrosine kinase enzyme comprising administering to a mammalian species in need of such treatment an effective amount of a compound of formula I, as defined above.
Additionally, the invention provides a method of treating a condition via modulation of at least one tyrosine kinase enzyme comprising administering to a mammalian species in need of such treatment an effective amount of a compound of formula I, as defined above, in combination (simultaneously or sequentially) with at least one other anti-cancer agent. : A preferred condition, treated by said methods of the instant invention, is cancer. Additionally, the tyrosine kinase enzyme may include (but is not limited to): ’ Abl, CDK’s, EGF, EMT, FGF, FAK, Flk-1/KDR, HER-2, IGF-1R, IR, LCK, MET,
PDGEF, Src, and VEGF.
The invention also provides a method for treating cancer, comprising administering to a mammalian species in need of such treatment, a therapeutically effective amount of at least one of the pharmaceutical compositions defined above.
The invention further provides a method for treating proliferative diseases, comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of at least one of the pharmaceutical compositions defined above.
Certain compounds of formula I may generally be prepared according to the following schemes and the knowledge of one skilled in the art. Solvates (e.g., hydrates) of the compounds of formula I are also within the scope of the present invention. Methods of solvation are generally known in the art. Accordingly, the compounds of the instant invention may be in the free or hydrate form, and may be obtained by methods exemplified by the following schemes below.
More specifically, Schemes I-VII illustrate the preparation of compounds claimed in this invention. The examples, which follow, illustrate the compounds that can be synthesized by these schemes. The schemes are not limited by the examples listed or by any substituents employed for illustrative purposes.
Scheme I describes the preparation of the benzimidazoles. The starting diamines 1 are readily available using literature methods or are obtained commercially. The diamine is then condensed with an aldehyde 2 to provide the benzimidazole 3. Further modification of the functional groups on the aryl group of the benzimidazole or heterocycle of 3 are then envisioned.
Scheme. rR? pg R® gp! vy PR
R® NH \ Ni R? N N
TX de - XX — a
LM I i Sg
R RE R’ R 1 2 3
Alternatively, the benzimidazole could be formed in a step-wise manner (see
Scheme II) by amide formation using the acid chloride of 5 or any of the commonly used peptide coupling reagents such as DCC (dicyclohexylcarbodiimide), EDCI (1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), etc. Once the amide 6 was formed the nitro group could be reduced using catalytic hydrogenation, transfer hydrogenation or chemical reduction such as SnCl, or iron powder or other methods known in the art for reduction of aryl nitro groups. Treatment of the aniline with acid would then form the benzimidazole.
Scheme IL
Y FR
R? gt R? BL
R? NH \ Nil R® NR' xX ou 2 rt dehydration Or RE WR’
RS ab CR RS 4 5 6
Y, R®
R? Ln R” py gr a NR? 3 x reductiog, Besse
R* NO, H R* No) x,
Rr RS R R 6 3
For example, Scheme III illustrates the use of 4-iodo-2-methoxy-pyridine-3- carbaldehyde 7 to provide the functionalized benzimidazole 8. Hydrolysis of the methoxy group using protic acid conditions, TMSI (trimethylsilyl iodide), BBr3, or other conditions known in the art for cleaving a methyl ether would provide the halopyridone 9. Addition of heteroatom nucleophiles using amines, alcohols or thiols would then provide the substituted pyridones 10. Other functionality could be . 20 incorporated into the aldehyde and the above example is included for illustrative purposes only.
Scheme 111 2 1 2 , © 8 MeO a RMeo
R NH — R = AN HCI
RY ——m 4 \ /
R* NH, o 7 R* N , }
AS Vw RS rR 1 7 8 2 1 )
R R' 0 3 7 R Q
A? N NH RH © N NH / R® 4 \ J R ge NAW , X=NHS0 R* N ,
RS cil R RS RX R 9 10
Likewise the aryl ring of the benzimidazole prepared using Schemes I or II can be modified. For example introduction of a cyano group for R® on the benzimidazole allows for the formation of heterocycles such as imidazole, imidazolines, oxazolines, thiazolines, amides, or amidines. Scheme IV illustrates such transformations. Starting from the cyano-substituted benzimidazole 11 the heterocycle can be modified as illustrated in Scheme IV to provide 12. Imidate formation preferably using ethanol and acid provides intermediate 13. Imidate 13 can be transformed using diamines to form imidazolines, amino alcohols to form oxazolines, amino acetals to form imidazoles, and amino thiols to form thiazolines 14.
Alternatively the imidate can be hydrolyzed to the acid and coupled with amines using any of the standard amide formation reagents (DCC, EDCI, etc.) to form amides 15. Imidate 13 is also a useful intermediate for the preparation of amidines 16 by reacting with amines.
Scheme IV
RRQ "Ro
NC N NH RxH NC N NH qe HCUELOH —— / —————— at NZ x-muso ge No) {. poof FR RE RXR " 12
OEt R? A! fo)
HN N NH
. an Wan
NH,RZH R 7 RNH, (% R? vo ~ RRC RN" wom ogg
U 13 +
N N NH H.N N NH
R N H,0 R N
RS RX R’ | DCC, R'R"NH RS RX. R’ 14 16 0 RR Rg 7 - Nv 7
RS RX FR’ 15
X=NH,0,S
Scheme V illustrates further transformation of benzimidazoles that bear a halogen atom using palladium catalysis using conditions developed by Suzuki [Yang et al. Acta Chem. Scand. (1993) 221; Suzuki et al. Synth. Commun. (1981) 11: 513] or Buchwald/Hartwig [Buchwald et al. J. Am. Chem. Soc. (1994) 116: 7901; Hartwig etal. J. Am. Chem. Soc. (1994) 116: 5969; Hartwig. Angew. Chem., Int. Ed. Engl. (1998) 37: 2046] and variations of these methods. Preparation of a bromide substituted benzimidazole 17 could be envisioned to provide a substrate for Suzuki coupling with aryl, vinyl, and heterocyclic boronic acids to provide benzimidazoles 18. Likewise, amines and heterocycles such as piperazine or morpholine derivatives 19 can be prepared from the same bromide using amines under conditions described by Buchwald and Hartwig or variations thereof.
Scheme V
Br N NH . ‘a Wa
Rr N
RS RX RA’
ArB(OH);, r 17 ING Pd
Y
ZY rR? R' 0 RZ glo x N NH ZYN N NH y R Re i” No? i” CN 7
RS RX WR RE RX FR
18 19
X=NH, 0,8
Alternatively amine and heterocyclic derivatives such as 19 can be prepared using intermediate 6 described in Scheme II. When the R'of6isa halogen, preferably F, the halogen can be displaced with amines, alcohols, heterocyclic amines and other nitrogen containing heterocycles such as piperazine, piperidine, 4-amino piperidine, morpholine, imidazole, etc (Scheme VI). The terminal nitrogen of piperazine or 4-amino piperidine can then be alkylated using standard alkylation conditions or reacted with aldehydes in a reductive amination reaction to provide alkylated derivatives. Alternatively the terminal nitrogen atom of piperazine or 4- amino piperidine can be acylated or carbamoylated using any number of conditions that are routine for someone skilled in the art of organic synthesis. Following the example illustrated in Scheme II compounds such as 19 could be prepared.
Scheme VL - 20
Y oO NH 2 2
FE NR' DX HNYZ ZYN N NH
R® RR’ rR
R* N : R* N X, 5 0, reduction 5 rR R’
R R
H* 6 19 N
Alternatively amines, heterocycles, and alcohols can be introduced at Rj using a nucleophilic aromatic substitution reaction started from an intermediate 20 were R3 is halogen, preferably F, the halogen can be displaced with amines, alcohols, heterocyclic amines and other nitrogen containing heterocycles such as piperazine, . 5 piperidine, 4-amino piperidine, morpholine, imidazole, etc (Scheme VII). The terminal nitrogen of piperazine or 4-amino piperidine can then be alkylated using standard alkylation conditions or reacted with aldehydes in a reductive amination reaction to provide alkylated derivatives. Alternatively the terminal nitrogen atom of piperazine or 4-amino piperidine can be acylated or carbamoylated using any number of conditions that are routine for someone skilled in the art of organic synthesis. The resulting nitro aniline could be reduced to the diamine 21 and processed as illustrated in Scheme III.
Scheme VIL 2
R* Nu I NH
F NH, Nu 1X 2 x reduction R? Rs NH;
RS
2 20
The compounds according to the invention have pharmacological properties; in particular, the compounds of formula I are tyrosine kinase enzyme inhibitors. The novel compounds of formula I are thus useful in the therapy of a variety of proliferative diseases (including but not limited to diseases associated with tyrosine kinase enzymes) such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurodegenerative disorders and cardiovascular disease. . More specifically, the compounds of formula I are useful in the treatment of a variety of cancers, including, but not limited to, the following: a) carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder,
ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; b) hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins } lymphoma, hairy cell lymphoma and Burkett’s lymphoma; c¢) hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; d) tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; e) tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and f) other tumors, including sacroma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
Due to the key role of tyrosine kinases in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
Compounds of formula I may induce apoptosis. The apoptotic response is aberrant in a variety of human diseases. Compounds of formula I, as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned herein above), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer’s disease, AIDS-related dementia, Parkinson’s disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
Compounds of formula I may modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus,
Epstein-Barr virus, Sindbis virus and adenovirus).
Compounds of formula I may also be useful in the chemoprevention of cancer.
Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre- malignant cells that have already suffered an insult or inhibiting tumor relapse.
Compounds of formula I may also be useful in inhibiting tumor angiogenesis and metastasis.
The compounds of this invention may also be useful in combination (administered together or sequentially) with known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and 3 anti-metabolites, such as methotrexate; tyrosine kinase inhibitors such as Iressa and
OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors;
Her1/2 inhibitors and monoclonal antibodies directed against growth factor receptors such as erbitux (EGF) and herceptin (Her2).
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent or treatment within its approved dosage range.
Compounds of formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of formula I may be administered either prior to or after administration of the known anticancer or cytotoxic agent(s).
Further subject matter of the invention also includes pharmaceuticals for use, as described above, including controlling cancer, inflammation and arthritis, which contain at least one compound of the formula I as defined above or at least one of its pharmacologically acceptable acid addition salts, and the use of a compound of the formula I as defined above for the preparation of a pharmaceutical having activity against proliferative diseases as described previously including against cancer, t5 inflammation and/or arthritis.
The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts.
Biological Assays
A. CDK 2/cyclin E Kinase Assay
Kinase reactions consisted of 5 ng of baculovirus expressed GST-
CDK2/cyclin E complex, 0.5 pg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 uCi **P y-ATP, 25 uM ATP in 50 pl kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl;, 1 mM EGTA, 2 mM DTT). Reactions were incubated for 45 minutes at 30° C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15%. TCA precipitates were collected onto
GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co., Meriden, CT) and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument
Co., Meriden, CT). Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (ICso). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 2%. ICs values were derived by non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 14%.
B. EMT Kinase Assay
A filter-based kinase assay, measuring the phosphorylation of Gst-SLP76 by
Gst-Emtk, was employed to determine the compound inhibitory activity against Emit.
The kinase reaction was performed in a 96-well plate at room temperature for 15 min before being terminated by adding 100 pl of 20% trichloroacetic acid (TCA) containing 0.1 M sodium pyrophosphate. The kinase reaction mixture (60 ul ) contained 25 mM HEPES, pH 7.0, 0.1 mg/ml BSA, 5S mM MgCl,, 5 mM MnCl, 8 ng of enzyme (Gst-Emtk), 5 pg of the substrate protein (Gst-SLP76), 1 uM ATP, 0.4 nCi of [y-p¥ JATP and the tested compound (at various concentrations). After termination, the proteins were allowed to precipitate in the presence of TCA for 1 hr at 4 °C. The precipitated proteins were then harvested on a filter plate (UniFilter-96,
GF/C, Packard Instrument) and washed to remove excess [y-P* JATP. The radioactivity was determined using a TopCount NXT (Packard Instrument) after adding 35 pl of Microscint 20 (Packard Instrument).
C. FAK Tyrosine Kinase Assay
The Focal Adhesion kinase was assayed using the synthetic polymer poly(Glu/Tyr) (Sigma Chemicals) as a phosphoacceptor substrate. Each reaction mixture consisted of a total volume of 50 ul and contained 100 ng of baculovirus- expressed enzyme, 2g of poly(Glu/Tyr), 1uM of ATP, and 0.2 uCi of [y-*P]ATP.
The mixtures also contained 40 mM Tris. HCI, pH 7.4, 1 mM MnCl, 0.5 mM DTT, and 0.1 mg/ml bovine serum albumin. The reaction mixtures were incubated at 26°C for 1 hour and kinase activity was determined by quantitation of the amount of radioactive phosphate transferred to the poly(Glu/Tyr) substrate. Incorporation was measured by the addition of cold trichloroacetic acid (TCA) precipitation of the proteins which were collected onto GF/C unifilter plates (Packard Instrument Co.,
Meriden, CT) using a Filtermate universal harvester and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Compounds were dissolved in dimethyl sulfoxide to a concentration of 10 mM and were evaluated at six concentrations, each in triplicate. The final concentration of DMSO added to the kinase assays was 0.5%, which has been shown to have no effect on kinase activity. IC50 values were derived non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
D. HER-1/HER-2 Kinase Assay
N Kinase reactions consisted of 10 ng of baculovirus expressed GST- HER, 100 ng of HER2, 100 ng/ml poly(Glu/Tyr) (Sigma), 0.2 pCi 33P y-ATP, 1 uM ATP in 50 ul kinase buffer (S50 mM Tris, pH 7.5, 10 mM MnCl2, 0.5 mM DTT). Reactions were incubated for 1h at 27 C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co., Meriden, CT) and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (ICsp). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 1%. ICs, values were derived by non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
E. IGF- Receptor Tyrosine Kinase Assay
The IGF-1 receptor tyrosine kinase was assayed using the synthetic polymer poly(Glu/Tyr) (Sigma Chemicals) as a phosphoacceptor substrate. Each reaction mixture consisted of a total volume of 50 ul and contained 125 ng of baculovirus expressed enzyme, 2.5ug of poly(Glu/Tyr), 25uM of ATP, and 0.1 uCi of [y- “P]ATP. The mixtures also contained 20 mM MOPS, pH 7.0, 5 mM MnCl, 0.5 mM
DDT, and 0.1mg/ml bovine serum albumin. The reaction mixtures were incubated at 30°C for 45 minutes and kinase activity was determined by quantitation of the amount of radioactive phosphate transferred to the poly(Glu/Tyr) substrate. Incorporation was measured by the addition of cold trichloroacetic acid (TCA) precipitation of the proteins which were collected onto GF/C unifilter plates (Packard Instrument Co.,
Meriden, CT) using a Filtermate universal harvester and the filters were quantitated } 5 using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Compounds were dissolved in dimethyl sulfoxide to a concentration of mM and were evaluated at six concentrations, each in triplicate. The final concentration of DMSO added to the kinase assays was 0.5%, which has been shown to have no effect on kinase activity. IC50 values were derived by non-linear 10 regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
F. Insulin Receptor Tyrosine Kinase Assay
The Insulin Receptor Tryrosine kinase was assayed using the synthetic polymer poly(Glu/Tyr) (Sigma Chemicals) as a phosphoacceptor substrate. Each reaction mixture consisted of a total volume of 50 ul and contained 90 ng of baculovirus-expressed enzyme, 2.51g of poly(Glu/Tyr), 25uM of ATP, and 0.1 uCi of [y- P]ATP. The mixtures contained also 20 mM Tris.HCI, pH 7.4, 5 mM MnCl, 0.5 mM DTT, and 0.1 mg/ml bovine serum. The reaction mixtures were incubated at 26°C for 1 hour and kinase activity was determined by quantitation of the amount of radioactive phosphate transferred to the poly(Glu/Tyr) substrate. Incorporation was measured by the addition of cold trichloroacetic acid (TCA) precipitation of the proteins which were collected onto GF/C unifilter plates (Packard Instrument Co.,
Meriden, CT) using a Filtermate universal harvester and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Compounds were dissolved in dimethyl sulfoxide to a concentration of 10 mM and were evaluated at six concentrations, each in triplicate. The final concentration of DMSO added to the kinase assays was 0.5%, which has been shown to have no effect on kinase activity. IC50 values were derived non-linear regression ‘ 30 analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
G. LCK Kinase Assay
Kinase reactions consisted of 10 ng of baculovirus expressed 10ng GST-Lck, 100 ng/ml poly(Glu/Tyr) (Sigma), 0.2 uCi 33P y-ATP, 1 uM ATP in 50 ul kinase , buffer (50 mM Tris, pH 7.5, 10 mM MnCl2, 0.5 mM DTT). Reactions were incubated for 1h at 27 C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co., Meriden, CT) and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (ICsp). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 1%. ICs values were derived by non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
H. MET Kinase Assay
Kinase reactions consisted of 10ng of baculovirus expressed GST-Met, 2.5ug poly(Glu/Tyr) (Sigma), 0.2uCi 33P y-ATP, 10 uM ATP in 50 pl kinase buffer (40mM Tris, pH 7.5, ImM MnCI2, 0.50 mM DTT). Reactions were incubated for 1h at 27 C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 3.5%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co., Meriden, CT) and the filters were quantitated using a : TopCount 96-well liquid scintillation counter (Packard Instrument Co., Meriden, CT).
Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (ICsp). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at seven concentrations, each in triplicate. .
The final concentration of DMSO in the assay equaled 1%. ICsp values were derived by non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
1. PDGF Receptor Kinase Assay
Kinase reactions consisted of 70ng of baculovirus expressed GST-PDGFbR, 0.3ug biotinylated poly(Glu/Tyr) (Sigma), in 50 pl kinase buffer (20 mM Hepes, pH 7.5,0.7uM ATP, 10mM MnCI2, 0.5mM DTT, 0.15mM NaCl, 0.1mg/ml BSA). : Reactions were incubated for 30 minutes at room temperature with shaking and stopped by the addition of 10ul of 0.2M EDTA, pH8.0. 150ul of HTRF detection buffer was added and incubated for 1 hour and 30 minutes at room temperature.
Counts were quantitated on Discovery HTRF Packard Instrument.
J. VEGFR-2 (KDR) Kinase Assay
Kinase reactions consisted of 7.5ng of baculovirus expressed GST-KDR, 1.5ug poly(Glu/Tyr) (Sigma), 0.04uCi 33P y-ATP, 2.5 pM ATP in 50 pl kinase buffer (25 mM Tris, pH 7.5, 1.8 mM MnCI2, 0.0.625 mM DTT). Reactions were incubated for 1h at 27 C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates were collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, CT) using a Filtermate universal harvester (Packard Instrument Co., Meriden, CT) and the filters were quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co.,
Meriden, CT). Dose response curves were generated to determine the concentration required to inhibit 50% of kinase activity (ICsg). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at six concentrations, each in triplicate. The final concentration of DMSO in the assay equaled 1%. ICsp values were derived by non-linear regression analysis and have a coefficient of variance (SD/mean, n=6) = 16%.
K. Cytotoxicity assay (HT-29-colon; Colo205, MCF-7-breast)
Tumor cell lines are maintained in McCoy’s SA medium (GIBCO) and 10% heat inactivated fetal bovine serum (GIBCO). The in vitro cytotoxicity is assessed in tumor cells by a tetrazolium-based colorimetric assay which takes advantage of the metabolic conversion of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium, inner salt) (Promega) to a reduced form that absorbs light at 492 nm (1). Cells are seeded 24 hr prior to drug addition. Following a 72 hour incubation at 37°C with serially diluted test compound,
MTS (Riss, T.L, et al., Comparison of MTT, XTT, and a novel tetrazolium compound
MTS for in vitro proliferation and chemosensitivity assays.," Mol. Biol. Cell 3 (Suppl.):184a, 1992), in combination with the electron coupling agent phenazine methosulfate, is added to the cells. The incubation is continued for 3 hours, then the absorbency of the medium at 492 nm is measured with a spectrophotometer to obtain the number of surviving cells relative to control populations. The results are expressed as median cytotoxic concentrations (ICso values).
Table 1 - Biological Activity (uM); all compounds in the table had kinase activity of <25uM against one or more of the following kinases CDK, EMT, FAK, Herl, Her2, IGF,
IR, LCK, MET, PDGF, VEGF. HT-29 and Colo205 are human colon tumor cell lines, and
MCF-7 is a human breast tumor cell line.
HT-29 | MCF-7 | Colo205 3 Jeo | TT 399 loa | Jos 400 08 | ]09 411 Joz | 109 s17 jo3 |b] 519 03 Joe (520 [oe Jo2 [521 jos 522 lo7_ Jor [or 523 Joe 1524 Joe
ERIN
526 14 | 0 1534 loa | 1 [538 ~~ joo | [ [544 Jo3 Joe [553 09 Jo3 Jo2 555 Jo2 Joa [o2 559 Joe loz 574 Jo2 [581 jo2 Jo3 [582 for Jo2
(584 03 Joa 58s Jor fos [ 590 [08 Jo2 [02 503 Jo7 [ ) General Procedure for the Preparation of 2-Hydroxy-2-(substituted-phenyl)-
OH ci NO, or 1-(3-Chloro-phenyl)-2-nitro-ethanol: To a solution of 3-chloro-benzaldehyde (20 g, 0.142 mol) in nitromethane (100 mL) were added magnesium sulfate (37.6 g, 0.312 mol) and phosphazene base P,-t-bu-tris(tetramethylene) (4.43 g, 0.014 mol). The reaction mixture was stirred at room temperature for 2 h. After concentration in vacuo, the residue was purified by flash chromatography (25% EtOAc / hexane) to yield the title compound (26.4 g, 100%) as a green-yellow oil. '"H NMR (300 MHz,
DMSO-dg) 6 7.53 (1H, s), 7.35 —- 7.42 (3H, m), 6.23 (1H, broad s), 5.32 — 5.33 (1H, m), 4.90 (1H, dd, J =3.2, 12.4 Hz), 4.60 (1H, dd, J = 1.2, 12.4 Hz).
OTES
RO
[1-(3-Chloro-phenyl)-2-nitro-ethoxy]-triethyl-silane: To a solution of 1-(3-chloro- phenyl)-2-nitro-ethanol (26 g, 0.14 mol) in DMF (50 mL) were added imidazole (28.6 g, 0.42 mol) and chlorotriethylsilane (25.3 g, 0.17 mol). The reaction mixture was stirred at room temperature for 2 h. After quenching with water, the mixture was extracted with ethyl acetate. The combined organic layers were washed with water - and brine, dried over Na,SO,, and filtered. After removal of solvent, the crude product was purified by flash chromatography (2% EtOAc / hexane) to yield the title compound (37 g, 91%) as a colorless oil. 'H NMR (300 MHz, CDCl) & 7.40 (1H, s), : 7.27-17.32 (3H, m), 5.40 (1H, dd, J =3.2,9.5 Hz), 4.51 (1H, dd, J = 9.5, 12.1 Hz), 4.36 (1H, dd, J =3.3,12.1 Hz), 0.85 (9H, t, J = 7.5 Hz), 0.54 (6H, q, J = 7.5 Hz).
OTES
2-(3-Chloro-phenyi)-2-triethyisilanyloxy-ethylamine: Raney nickel (1 g) was washed with distilled water five times and methanol three times. [1-(3-Chloro- : phenyl)-2-nitro-ethoxy]-triethyl-silane (10 g, 0.032 mol) and Raney nickel in methanol (100 mL) was hydrogenated (35 psi) at room temperature for 14 h. The reaction mixture was filtered through a pad of celite and rinsed with methanol.
Concentration of the filtrate to dryness gave the title compound (5.6 8, 62%) as a colorless oil which was used for the next step without purification. 'H NMR (300
MHz, CDCl3) 6 7.32 (1H, s), 7.18-7.26 (3H, m), 4.70 (1H, t, J = 5.8 Hz), 2.86 (2H, m), 0.89 (9H, t, J = 7.9 Hz), 0.56 (6H, q, J = 7.8 Hz). LRMS (M+H)* m/z 286.
General Procedure for the Preparation of 2-Hydroxy-2-(substituted-phenyl)- ethylamines: [o}
Br [+] 4-methoxy-3-bromophenyl chloroacetophenone: To a suspension of AlCl; (13.4g, 0.10 mol) in methylene chloride (40mL) was added a solution of 2-bromoanisole (12.5 mL, 0.10 mol) and chloroacetyl chloride (8 mL, 0.10 mol) at 0°C. The solution was warmed to ambient temperature for two hours and poured onto ice and extracted with methylene chloride, washed with saturated sodium bicarbonate solution, brine, and dried over MgSO. The solution was filtered, concentrated and crystalized from
EtOH to give 15.37g of white solid. LRMS [M-HJ- 260.8; IR (KBr) 1697, 1048, 1255 cm’; 'H NMR (300MHz, CDCl,) 6 8.18 (s, 1H), 7.94 (dd, J= 8.67 Hz, 1H), 6.96 (d,
J=8.67 Hz, 1H), 4.62 (s, 2H), 3.98 (s, 3H); 'C NMR (CDCl, 75.5 Hz) & 188.8, 160.3, 134.1, 129.9, 128.2, 112.4, 111.3, 56.6, 45.3.
General Procedure for chiral reduction of chleroketones and ammonolysis : ’
OH
Br ~ Cl (S)-1-[4-methoxy-3-bromophenyl] —2-chloro ethanol : To a solution of (S)-Methyl- : CBS-oxazaborolidine (1M in toluene, 0.745 mL, 0.745 mmol) and BH3;-THF (8mL, 8 mmol) was added at the same time a solution of BH3-THF (19mL, 19 mmol) and a solution of the chloroketone (10.03g, 37.98 mmol) in 19 mL of THF. Both solutions were added dropwise over 30 minutes. The solution was stirred for 1 hour and quenched with the slow addition of methanol (50mL). The solution was concentrated and the residue chromatographed over a short silica gel column (1:1 hexane/ethyl acetate) to give a quantitative yield (10.0g) of chlorohydrin as a clear oil. IR (KBr) 1053, 1258, 3406 cm’; 'H NMR (300MHz, CDCl) 6 7.59 (s, 1H), 7.30 (dd, J=2.16
Hz, 1H), 6.90 (d, J=8.46 Hz, 1H), 4.83 (dd, J= 3.57 Hz, 1H), 3.90 (s, 3H), 3.64 (ddd,
J=3.6,11.1, 8.7, 2H), 2.04 (b s, 1H). “c NMR (CDCl,, 75.5 MHz) 6 155.9, 133.5, 131.1, 126.3, 111.9, 73.1, 60.4, 56.3, 50.7.
OH
Br A NHZHCI
Beh (S) 2-Amino-1-[3-chloro-4-methoxyphenyl]ethanol Hydrochloride : To a solution of the chlorohydrin (10.0g, 37.9 mmol) in 120 mL of methanol at 40°C was added 100 grams of ammonia. The solution was sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution was cooled and opened.
The ammonia was allowed to evaporate and solution concentrated. The residue was crystalized from ethanol/ethyl acetate to give 3.83g of white solid (35%). The material was reacted with Boc,O in ethyl acetate and saturated sodium bicarbonate and analyzed by chiral HPLC using a chiralcel OJ column using 95% hexane/ethanol as elutant and determined to by 98%ee. Additional crops were collected — 2.96g and 1.41g for a total of 75% yield. LRMS [M+H]+ 246; IR (cm™, KBr) 1055, 1261, 3001, 2948, 3356; 'H NMR (500MHz, DMSO) 6 8.09 (bs, 2 H), 7.58 (s, 1H), 7.36 (dd, J=2.05, 6.45 Hz, IH), 7.11 (d, J=8.5 Hz, 1H) 6.10 (s, 1H), 4.80 (m, 1H), 3.84 (s,
3H), 3.00 (ddd, J=2.7, 12.6, 9.5 Hz, 2H); Pc NMR (DMSO, 75.5 MHz) 6 154.8, 135.4, 1304, 126.6, 112.4, 110.4, 67.9, 56.2, 45.4. oH
RO
S
(S) 2-Amino-1-[3-chlorophenyljethanol Hydrochloride : was prepared according to the general procedure outlined above. LRMS [M+H]+ 172; IR (KBr, cm-1) 3048, 3351, 2952; 'H NMR (300MHz, MeOD) 6 7.48 (5, 1H), 7.35 (m, 3H), 3.31 (ddd, J= 1.5,3.12, 9.15 Hz 2H).
OH
ROH
(S)-2-Amino-1-[3-bromophenyljethanol Hydrochloride : was prepared according to the general procedure outlined above. LRMS [MH]+ 217.9; IR (KBr, cm-1) 3025, 3443,2891; 'H NMR (S00MHz, DMSO) 8 7.93 (b s, 2H), 7.60 (s, 1H), 7.52 (d, 1H), 7.41 (s, 1H), 7.35 (d, J=7.7 Hz, 1H) 6.17 (s, 1H), 4.82 (m, 1H), 3.08 (ddd, J=2.6, 12.7, 9.6 Hz, 2H); Ne NMR (DMSO, 75.5 MHz) 6 144 4, 130.5, 128.7, 125.0, 121.6, 68.3, 45.1.
OM
ROSA
MeS (S)-2-Amino-1-[3-chloro-4-methylthiophenyl]ethanol Hydrochloride : was prepared according to the general procedure outlined above. LRMS [M+H]+ 217.9;
IR (KBr, cm-1) 3007, 3358; 'H NMR (500MHz, DMSO) 6 8.12 (b s, 2H), 7.46 (s, 1H), 7.37 (s, 1H), 7.35 (d, 1H) 6.19 (d, 1H), 4.83 (m, 1H), 3.01 (ddd, J=3.2, 12.8, 9.3 3 i
Hz, 2H); C NMR (DMSO, 75.5 MHz) & 139.6, 136.5, 129.8, 126.6, 125.4, 68.0, 45.2, 14.2.
OH ct = _NHyHCI
ATT
(S)-2-Amino-1-[3-chloro-4-fluoro-phenyl]lethanol Hydrochloride : was prepared - according to the general procedure outlined above. LRMS [M+H]+ 189.9; IR (KBr, cm-1) 1509, 3008, 3359; '"H NMR (500MHz, DMSO) 6 8.21 (bs, 2H), 7.61 (d,
J=7.85 Hz, 1H), 7.42 (m, 2H), 6.29 (s, 1H), 4.88 (m, 1H), 3.03 (ddd, J=3.4, 12.8,9.2
Hz, 2H); 'C NMR (DMSO, 75.5 MHz) 8 157.5, 155.5, 139.7, 128.1, 126.7, 119.3, 116.7, 109.0, 67.8, 45.2.
OH cl A NH HCI (S)-2-Amino-1-[3-chloro-4-methoxyphenyl]lethanol Hydrochloride : was prepared according to the general procedure outlined above. LRMS [M+H]+ 202; IR (KBr, cm-1) 3354, 3003, 2949, 1288, 1064; 'H NMR (500MHz, DMSO) 6 8.18 (brs, 3H), 7.43 (d, J=2.0Hz, 1H), 7.31 (dd, J=8.5, 2.0Hz, 1H), 7.14 (d, J=5.1Hz, 1H), 6.11 (s, 1H), 4.81 (m, 1H), 3.84 (s, 3H), 2.99 (dd, J=13, 3.5Hz, 1H), 2.83 (dd, J=12.5, 9Hz, 1H); “Cc NMR (DMSO, 125MHz) § 153.9, 135.0, 127.3, 125.8, 120.8, 112.6, 68.0, 56.1, 45.5; Elemental Analysis Calcd for CoH;2CINO,-HCL: C, 45.39; H, 5.50; N, 5.88. Found: C, 45.38; H, 5.43; N, 5.70.
OH
Br ~__NHzHCI
Lr (S)-2-Amino-1-(7-bromo-2,3-dihydrobenzfuran-5-yl)-2-aminoethanol ' Hydrochloride : was prepared according to the general procedure outlined above.
LRMS [M+H]}+ 258; IR (KBr, cm-1) 3349, 3006, 2928, 1485, 1045, 983; 'H NMR (500MHz, DMSO) 6 8.13 (brs, 3H), 7.29 (s, 1H), 7.23 (s, 1H), 6.08 (d, J=4 Hz, 1H), 4.76 (m, 1H), 4.61 (t,J=9Hz, 2H), 3.29 (t, J=9Hz, 2H), 2.96 (dd, J=13, 3.5Hz, 1H),
2.82 (dd, J=13,9.5Hz, 1H); “c NMR (DMSO, 125MHz) 6 156.3, 135.9, 129.1, 128.1, 122.1, 100.9, 71.5, 68.2, 45.6, 29.9; Elemental Analysis Calcd for
CioH12BINO,-HCI: C, 40.77; H, 4.44; N, 4.75. Found: C, 40.77; H, 4.63; N, 4.63.
General Procedure for the Preparation of 2-Amine-3-(substituted-phemyl)- : propanol: “OMT
OH °o (5)-[2-(3-Bromo-phenyl)-1-hydroxymethyl-ethyl]-carbamic acid tert-butyl ester:
To a solution of (S)-3-(3-bromo-phenyl)-2-tert-butoxycarbonylamino-propinic acid (500 mg, 1.45 mmol) in THF (30 mL) was added borane-tetrahydrofuran complex (1.0 M solution) (4.35 mL, 4.35 mmol). The reaction mixture was stirred at room temperature for 14 h and quenched with acetic acid (1 mL). After removal of most solvent, the residue was extracted with EtOAc, washed with brine, dried over Na,SOj,.
After concentration, the crude product (400 mg, 83%) was used for the next step without purification. LCMS (M+H)" m/z 330 (t = 1.61 min
Br NH;
UL, (S)-2-Amino-3-(3-bromo-phenyl)-propan-1-ol: To a solution of (§)-[2-(3-bromo- phenyl)-1-hydroxymethyl-ethyl}-carbamic acid rerr-butyl ester (400 mg, 1.21 mmol) in methanol (30 mL) was added 4 M HCl in dioxane (2 mL, excess). The reaction mixture was stirred at room temperature for 14 h. After concentration in vacuo, the residue was used for the next step without purification. LCMS (M+H)* m/z 230 (t = 0.78 min.) [o} .
Cl (] 0
5-Chloroacetyl-7-chlorooxindole: To a suspension of AICI; (13.4g, 0.10 mol) in methylene chloride (40mL) is added a solution of 7-Chlorooxindole (0.10 mol) and chloroacetyl chloride (8 mL, 0.10 mol) at 0°C. The solution is warmed to ambient temperature for two hours and poured onto ice and extracted with methylene chloride, washing with saturated bicarbonate solution, brine, and drying over MgSO,4 would provide the desired chloroketone.
OH
Cl ~ (o]]
LT o (S)-7-Chloro-5-(2-chloro-1-hydroxy-ethyl)-2-oxoindole : To a solution of (S)-
Methyl-CBS-oxazaborolidine (1M in toluene, 0.745 mL, 0.745 mmol) and BH;-THF (8mL, 8 mmol) is added at the same time a solution of BH3;-THF (19mL, 19 mmol) and a solution of the 5-Chloroacetyl-7-chlorooxindole (37.98 mmol) in 19 mL of
THF. Both solutions are added dropwise over 30 minutes. The solution is stirred for 1 hour and quenched with the slow addition of methanol (50mL). The solution is concentrated and the residue chromatographed over a short silica gel column (1:1 hexane/ethyl acetate).
OH cl A NHzHCI
WS
[0] (S)-2-Amino-1-(7-chlorooxindole-5-yl)-ethanol Hydrochloride : To a solution of the chlorohydrin (37.9 mmol) in 120 mL of methanol at 40°C is added 100 grams of ammonia. The solution is sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution is cooled and opened. The ammonia is allowed to evaporate and solution concentrated to provide the hydrochloride salt, which can be crystallized from ethanol/ethyl acetate.
o
Cl Cl
Rea a 6-Chloroacetyl-4-chloro-2-benzooxazolinone: To a suspension of AlCl; (13.4g, 0.10 mol) in methylene chloride (40mL) is added a solution of 4-chloro-2- benzooxazolinone (0.10 mol) and chloroacetyl chloride (8 mL, 0.10 mol) at 0°C. The solution is warmed to ambient temperature for two hours and poured onto ice and extracted with methylene chloride, washing with saturated bicarbonate solution, brine, and drying over MgSO4 would provide the desired chloroketone.
OH
Cl ~ Cl nS o (S)-6-(2-Chloro-1-hydroxy-ethyl)-4-chloro-2-benzooxazolinone: To a solution of (S)-Methyl-CBS-oxazaborolidine (1M in toluene, 0.745 mL, 0.745 mmol) and BH3-
THF (8mL, 8 mmol) is added at the same time a solution of BH3-THF (19mL, 19 mmol) and a solution of the 6-Chloroacetyl-4-chloro-2-benzooxazolinone (37.98 mmol) in 19 mL of THF. Both solutions are added dropwise over 30 minutes. The solution is stirred for 1 hour and quenched with the slow addition of methanol (50mL). The solution is concentrated and the residue chromatographed over a short silica gel column (1:1 hexane/ethyl acetate).
OH . cl 2 _ NH HCI
J
[o) (S)-2-Amino-1-(4-chlero-2-benzooxazolinone-6-yl)-ethanol Hydrochloride : To a solution of the chlorohydrin (37.9 mmol) in 120 mL of methanol at —40°C is added 100 grams of ammonia. The solution is sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution is cooled and opened.
The ammonia is allowed to evaporate and solution concentrated to provide the hydrochloride salt, which can be crystallized from ethanol/ethyl acetate.
Cl
N-Methyl-7-chloroindoline: To a solution of the 7-Chloroindoline (0.10 mol) in 500 mL of acetone is added K,COj; (0.15mol) and Mel (0.15mol) and refluxed until the starting material is consumed. The reaction is filtered and washed with water and saturated bicarbonate solution, drying over MgSO,4 would provide the N-Me -7- chloroindoline o
Ct Cl
MeN N-Methyl-5-chloroacetyl-7-chloro-indoline: To a suspension of AICI; (13.4g, 0.10 mol) in methylene chloride (40mL) is added a solution of N-Me-7-Chloroindoline (0.10 mol) and chloroacetyl chloride (8 mL, 0.10 mol) at 0°C. The solution is warmed to ambient temperature for two hours and poured onto ice and extracted with methylene chloride, washing with saturated bicarbonate solution, brine, and drying over MgSO, provides the desired chloroketone.
OH a AC
FT
(S)-N-Methyl-5-(2-chloro-1-hydroxylethyl)-7-chloro-indoline: To a solution of (S)- : 25 Methyl-CBS-oxazaborolidine (1M in toluene, 0.745 mL, 0.745 mmol) and BH3;-THF (8mL, 8 mmol) is added at the same time a solution of BH3;-THF (19mL, 19 mmol) ’ and a solution of N-Methyl-5S-chloroacetyl-7-chloro-indoline (37.98 mmol) in 19 mL of THF. Both solutions are added dropwise over 30 minutes. The solution is stirred for 1 hour and quenched with the slow addition of methanol (50mL). The solution is concentrated and the residue chromatographed over a short silica gel column (1:1 hexane/ethyl acetate).
OH cl ~__ NHyHCI wl (S)-2-Amino-1-(7-chloro-N-methyl-indoline-5-yl)-ethanol Hydrochloride : To a solution of the chlorohydrin (37.9 mmol) in 120 mL of methanol at —40°C is added 100 grams of ammonia. The solution is sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution is cooled and opened.
The ammonia is allowed to evaporate and solution concentrated to provide the hydrochloride salt, which can be crystallized from ethanol/ethyl acetate.
OH cl Cl neh (S)-2-Chloro-1-(7-chloro-N-methyl-indol-5-yl)-ethanol: A solution (S)-N-Methyl- 5-(2-chloro-1-hydroxylethyl)-7-chloro-indoline (0.10 mmol) in 100mL of t-butyl methyl ether is treated with o-chloroanil (0.10mmol) at ambient temperature. The solution is concentrated and the residue chromatographed over silica gel (1:1 hexane/ethyl acetate) to provide the corresponding indole.
OH : cl = NH HCI wT (S)-2-Amino-1-(7-chloro-N-methyl-indol-5-yl)-ethanol Hydrochloride : Toa solution of the chlorohydrin (37.9 mmol) in 120 mL of methanol at 40°C is added 100 grams of ammonia. The solution is sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution is cooled and opened.
The ammonia is allowed to evaporate and solution concentrated to provide the hydrochloride salt, which can be crystalized from ethanol/ethyl acetate. ’ cl
J
Jy 4-Chloro-2-methyl-benzooxazole : To a solution of the 4-chloro-2- benzooxazolinone (0.10 mol) in 200 mL ethanol is added LiOH (0.20 mol) in 100 mL of water. The solution is refluxed for 8 hr and cooled. The solution is neutralized with IN HCI and extracted with ethyl acetate followed by drying over MgSO4. The solution is concentrated and taken up in 200 mL of toluene and 0.10 mol of acetic acid. The solution is refluxed in a Dean Stark trap for 12 hours, concentrated and purified by flash chromatography. o [>] Ct
POA
Js 6-Chloroacetyl-4-chloro-2-methyl-benzooxazele: To a suspension of AICI; (13.4g, 0.10 mol) in methylene chloride (40mL) is added a solution of 2-Methyl-4-chloro- benzooxazole (0.10 mol) and chloroacetyl chloride (8 mL, 0.10 mol) at 0°C. The solution is warmed to ambient temperature for two hours and poured onto ice and extracted with methylene chloride, washing with saturated bicarbonate solution, brine, and drying over MgSO, would provide the desired chloroketone.
OH
Cl ~ Cl i (S)-6-(2-chloro-1-hydroxy-ethyl)-4-chloro-2-methyl-benzooxazole: To a solution of (S)-Methyl-CBS-oxazaborolidine (1M in toluene, 0.745 mL, 0.745 mmol) and
WQ 02/079192 PCT/USO2/09402
BH3-THF (8mL, 8 mmol) is added at the same time a solution of BH3-THF (19mL., 19 mmol) and a solution of 6-Chloroacetyl-4-chloro-2-methyl-benzooxazole (37.98 mmol) in 19 mL of THF. Both solutions are added dropwise over 30 minutes. The solution is stirred for 1 hour and quenched with the slow addition of methanol (50mL). The solution is concentrated and the residue chromatographed over a short silica gel column (1:1 hexane/ethyl acetate).
OH cl = _NHzHCI
Tr j= (S)-2-Amino-1-(4-chloro-2-methyl-benzooxazol-6-yl)-ethanol Hydrochloride : To a solution of the chlorohydrin (37.9 mmol) in 120 mL of methanol at —40°C is added 100 grams of ammonia. The solution is sealed in a pressure bottle and warmed to ambient temperature and stirred for 48 hours. The solution is cooled and opened.
The ammonia is allowed to evaporate and solution concentrated to provide the hydrochloride salt, which can be crystallized from ethanol/ethyl acetate.
Preparation of 3-(6-Imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-iodo-1H- pyridin-2-one:
En
Qh ) 1-(3-Methyl-4-nitro-phenyl)-1H-imidazole: To a solution of 4-fluoro-2-methyl-1- nitro-benzene (300 mg, 1.84 mmol) in DMSO (2 mL) were added KOH (20 mg, 3.87 mmol) and imidazole (263 mg, 3.88 mmol). The reaction mixture was heated to 100°C for 3.5 h, cooled to room temperature, and diluted with ice-cold water. The resulting precipitate was filtered, washed with ice-cold water, and dried under vacuum to give the title compound (310 mg, 80%) as a yellow powder. 'H NMR (300 MHz,
DMSO-d¢) 6 8.46 (1H, 5), 8.16 (1H, d, J = 8.9 Hz), 7.90 — 7.92 (2H, m), 7.78 (1H, dd,
J=125,89 Hz), 7.17 (1H, s), 2.61 (3H, s). LRMS (M+H)" m/z 204. gt : a,
S : 4-Imidazol-1-yl-2-methyl-phenylamine: To 1-(3-methyl-4-nitro-phenyl)-1H- imidazole (200 mg, 0.98 mmol) and 10% Palladium on carbon (35 mg) was added degassed methanol (3 mL). The suspension was flushed and evacuated with hydrogen / vacuum line. The suspension was allowed to stir at room temperature for 14 h under hydrogen atmosphere (hydrogen balloon). The dark reaction mixture was filtered through a pad of celite and rinsed with methanol. Concentration of the filtrate gave the title compound (166 mg, 98%) which was used for the next step without purification. '"H NMR (300 MHz, DMSO-d) & 7.95 (1H, s), 7.48 (1H, ss), 7.16 (1H, narrow d, J = 2.5 Hz), 7.09 (1H, dd, J = 2.5, 8.4 Hz), 7.01 (1H, 5), 6.67 (1H, d, J=8.4
Hz), 5.03 (2H, broad s), 2,10 (3H, s). oy
NH
PN
N-(4-Imidazol-1-yl-2-methyl-6-nitro-phenyl)-acetamide: To a solution of 4- imidazol-1-yl-2-methyl-phenylamine (1 g, 5.78 mmol) in CH,Cl, (20 mL) was added
Acy0 (0.7 mL, 7.28 mmol) at 0°C. The reaction mixture was stir at room temperature for 14 h and diluted with water. The aqueous layer was extracted with CH,Cl, and the combined organic layers were washed with saturated NaHCOs and brine, dried over
Na;S0Os, and concentrated in vacuo to give a white solid. The white solid was : 25 suspended in H2SO4 (conc.) (15 mL). Then HNO; (conc.) (0.312 mL) was added to the suspension at 0°C. The reaction mixture was slowly warmed to room temperature and stirred at room temperature for 4 h. After cooling to -10°C, the reaction mixture was neutralized with ammonium hydroxide and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na,SO,, and concentrated. The residue was purified by flash chromatography (1:9:5 MeOH / THF / hexane) to yield the title compound (0.61 g, 41%). '"H NMR (300 MHz, CD;0D) & 8.11 (1H, ss), 7.45 - 7.56 (2H, m), 7.38 (1H, dd, J = 2.4, 8.4 Hz), 7.14 (1H, 5), 2.33 (3H, s), 2.18 (3H, s). gi! NO,
S
4-Imidazol-1-yl-2-methyl-6-nitro-phenylamine: To a suspension of N-(4-imidazol- 1-yl-2-methyl-6-nitro-phenyl)-acetamide (279 mg, 1.07 mmol) in ethanol (3 mL) was added 2 N HCI (2 mL). The reaction mixture was heated to reflux for 14 h, cooled to room temperature, and neutralized with saturated NaHCO. The resulting bright orange solid was filtered and dried under vacuum. The title compound (179 mg, 76%) was obtained as an orange solid. 'H NMR (300 MHz, CDsOD) 6 8.78 (1H, s), 8.24 (1H, s), 7.78 (1H, s), 7.64 (1H, s), 7.46 (1H, s), 2.36 (3H, s). yg! NH, ps
S-Imidazol-1-yl-3-methyl-benzene-1,2-diamine: To 4-imidazol-1-yl-2-methyl-6- nitro-phenylamine (350 mg, 1.61 mmol) and 10% Palladium on carbon (40 mg) were added degassed methanol (5 mL) and TFA (5 drops). The reaction mixture was flushed and evacuated with hydrogen / vacuum line, stirred at room temperature for 14 h under hydrogen atmosphere (hydrogen balloon). The dark reaction mixture was filtered through a pad of celite and rinsed with methanol. Concentration of the filtrate gave the residue, which was diluted with water, extracted with ethyl acetate. The combined organic layers were washed with saturated NaHCOs, brine, dried over
Na,SOs. Concentration to dryness gave the title compound (275 mg, 91%) as a solid. 'H NMR (300 MHz, CD;0D) 8 7.87 (1H, 5), 7.34 (1H, 5), 7.05 (1H, 5), 6.72 (1H, d, J
= 2.4 Hz), 6.65 (1H, d, J = 2.4 Hz) 2.21 (3H, s). LCMS (M+H)* m/z 189 (t = 0.23 min.). gd 7 4-Iodo-2-methoxy-pyridine-3-carbaldehyde (WO 95/29917): A 5-liter three-necked round bottom flask was equipped with an overhead mechanical stirrer under nitrogen, the flask was charged with THF (1 L) and cooled to -78°C. To this stirred solution was added zert-butyllithium (1.7 M solution in pentane) (800 mL, 1.36 mol) via canula followed by 2-methoxypyridine (132.2 g, 1.21 mol) at -78°C. The mixture was stirred for 1 h at -78°C. To the mixture was added N-formyl-N, N°, N’- trimethylethylenediamine (176 mL, 1.37 mol) dropwise at -78°C. The reaction mixture was stirred for ca. 30 min at -78°C before warming to -23°C over ca. 30 min.
To the mixture at -23°C was added ethylene glycol dimethyl ether (1 L) followed by n-butyllithium (2.5 M solution in hexane) (800 mL, 2.0 mol). The resulting mixture was stirred for ca. 2 h during which time the reaction mixture turned deep green. A 12-L 4-necked round flask was charged with iodine (571 g, 2.25 mol) and ethylene glycol dimethyl ether (2 L) and the resultant solution was cooled to -78°C. The contents of the 5-L flask were transferred via canula to the mixture of iodine and ethylene glycol dimethyl ether in the 12-L flask at -78°C. After the addition was complete, the reaction mixture was stirred for an additional 1 h at -78°C. The cooling bath was removed and the mixture was allowed to warm to about 0°C and treated with 2 L of water and 2 L of 1 N hydrochloric acid. Methyl t-butyl ether (2L) was added and the layers were separated. The aqueous layer was extracted with 2 x 1 L of methyl t-butyl ether. The combined organic layers were washed with saturated Na;S,04 (1.2
L), brine (1.2 L), dried over Na;SO,4. After concentration in vacuo, the thick slurry was diluted with hexane (1 L). The mixture was cooled with an ice / water bath for ca. min. The precipitate was filtered and dried in vacuum to yield the title compound as a light yellow solid. '"H NMR (300 MHz, CDCl3) § 10.22 (s, 1H), 7.86 (1H, d, J =
5.3 Hz), 7.54 (1H, d, J = 5.3 Hz), 4.06 (3H, 5). LCMS (M+H)" m/z 364 (t = 2.26 min.). ! ns
B22 6-Imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole:
To a solution of 5-imidazol-1-yl-3-methyl-benzene-1,2-diamine (175 mg, 0.93 mmol) in methanol (8 mL) was added a solution of 4-iodo-2-methoxy-pyridine-3- carbaldehyde (245 mg, 0.93 mmol) in methanol (5 mL) at 0°C. The reaction mixture was stirred at 0°C for 1.5 h and then at room temperature for 2 h. After concentration, the residue was purified by flash column chromatography (10% MeOH / CH,Cl,) to give the title compound (291 mg, 60%). 'H NMR (300 MHz, CD;0D) & 8.13 (1H, s), 7.98 (1H, d,J=5.4 Hz), 7.62 (1H, d, J = 5.4 Hz), 7.59 (2H, s), 7.33 (1H, s), 7.16 (1H, s), 3.90 (3H, s), 2.67 (3H, s). LCMS (M+H)"* m/z 432 (t = 0.99 min.). gi! N 2 NH weds 3-(6-Imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-iodo-1H-pyridin-2-one:
The suspension of 6-imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H- benzimidazole in 1 N HCI (6 mL) was heated to 70°C for 3 days, cooled to room temperature, and diluted with ethyl acetate. After extraction, the combined organic layers were washed with brine, dried over Na;SO4 and concentrated. The residue was purified by flash chromatography (1% NH4OH / 10% MeOH / CH,Cl,) to yield the title compound (78 mg, 81%) as a solid. 'H NMR (300 MHz, CDs0D) 6 8.12 (1H, s), 7.58 (2H, s), 7.29 - 7.31 (2H, m), 7.16 (1H, s), 7.01 (1H, J = 6.8 Hz), 2.66 (3H, s). :
LCMS (M+H)" m/z 418 (t = 0.75 min.)
Preparation of 2-(4-Chloro-2-oxo-1,2-dihydro-pyridin-3-yl)-7-methvi-3H- benzimidazole-5-carbonitrile:
NC
CL, : 4-Amino-3-methyl-benzonitrile: To a solution of 3-methyl-4-nitro-benzonitrile (20 £0.123 mol) in HOAc (200 mL) was added iron powder (17.55 g, 0.309 mol). After min, the reaction was exothermic and turned to dark color. The reaction mixture was allowed to stir at room temperature for 14 h and then diluted with EtOAc (200 mL). The brown precipitate was filtered through a pad of celite and the filtercake was rinsed with EtOAc. The filtrate was concentrated in vacuo and the residue was 10 purified by flash chromatography (40% EtOAc / hexane) to yield the title compound (15.3 g, 92%). 'H NMR (300 MHz, CDCl3) 8 7.30 — 7.34 (2H, m), 6.64 (1H, d, J = 8.7 Hz), 2.16 (3H, s). LCMS (M+H)* m/z 133 (t = 0.93 min).
NC NO, w 07 CF,
N-(4-Cyano-2-methyl-6-nitro-phenyl)-2,2,2-trifluoro-acetamide: To the ice-cold trifluoroacetic anhydride (60 mL) was added 4-amino-3-methyl-benzonitrile (14.33 g, 0.108 mol) in portion. The resulting white slurry was stirred at 0°C for 30 min. Then ammonium nitrate (17.28 g, 0.216 mol) was added. The reaction mixture was allowed to stir at 0°C for 1 h and at room temperature for 14 h. After removal of most solvent, the reaction mixture was cooled with ice and quenched with ice. The yellow precipitate was filtered, washed with cold water, and dried under vacuum. The crude product (15.5 g, 52% yield, and ca. 80% pure) was used for the next step without purification. '"H NMR (300 MHz, CD;0D) § 8.05 (1H, 5), 7.74 (1H, s), 2.30 (3H, s).
LRMS (neg. ESI, (M-H)") m/z 272.
NC NO, je
4-Amino-3-methyl-5-nitro-benzonitrile: A mixture of N-(4-cyano-2-methyl-6-nitro- phenyl)-2,2,2-trifluore-acetamide (5 g, 18.3 mmol) and 2 M ammonia in methanol (80 mL) was heated to reflux for 14 h and then cooled to room temperature. Afier concentration in vacuo, the residue was purified by flash chromatography (20%
EtOAc / hexane) to yield the title compound (3.24 g, 100%, ca 80% pure). 'H NMR (300 MHz, CDCl;3) 6 8.40 (1H, s), 7.47 (1H, s), 6.6 — 6.8 (2H, broad s), 2.89 (3H, s).
NC NH, [Ss 3,4-Diamino-5-methyi-benzonitrile: To a solution of 4-amino-3-methyl-5-nitro- benzonitrile (3.24 g, 18.3 mmol) in ethanol (80 mL) was added tin chloride dihydrate (8.67 g, 49.75 mmol). The reaction mixture was heated to reflux for 14 h, then cooled to room temperature, and concentrated in vacuum. The residue was diluted with ethyl acetate (100 mL) and treated with triethylamine (20 mL). The resulting slurry was filtered through a pad of celite and the filtercake was rinsed with three-portion ethyl acetate (50 mL). The filtrate was washed with saturated NaHCO;, water, and brine, then dried over Na,SO4 and filtered. After removal of solvent, the residue was purified by flash chromatography on silica gel (30% - 50% EtOAc / hexane) to yield the title compound (2.17 g, 81%) as a light yellow solid. 'H NMR (300 MHz, CDCls) 36.94 (1H, s), 6.85 (1H, 5), 2.16 (3H, 5). LCMS (M+H)"* m/z 148 (t = 0.67 min.).
Ne H MeO a
Cr
I
2-(4-lIodo-2-methoxy-pyridin-3-yl)-7-methyl-3H-benzimidazole-5-carbonitrile: To a solution of 3,4-diamino-5-methyl-benzonitrile (2.00 g, 13.6 mmol) in MeOH (40 mL) was added 4-iodo-2-methoxy-pyridine-3-carbaldehyde (3.6 g, 13.6 mmol) in
MeOH (20 mL) at 0°C. The resulting slurry was stirred at 0°C for 1 h. Iodine (1.73 g, 8.8 mmol) in MeOH (10 mL) was added dropwise via a dropping funnel to the reaction mixture at 0°C. The reaction mixture was stirred at room temperature for 14 h. After removal of MeOH, the residue was diluted with saturated Na;S,0; and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na;SO4. The crude product was purified by flash column chromatography (3% MeOH / CH,Cl,) to yield the title compound (1.81 g, 46%). 'H } 5 NMR (300 MHz, CDCl3) 6 7.90 (1H, s), 7.49 (1H, d, J = 5.4 Hz), 7.46 (1H, s), 7.41 (1H, d, J = 5.3 Hz), 3.78 (3H, 5), 2.68 (3H, 5). LCMS (M+H)" m/z 391 (t = 1.27 min.).
NC N ° NH
Cris [+] 2-(4-Chloro-2-0x0-1,2-dihydro-pyridin-3-yl)-7-methyl-3H-benzimidazole-5- carbonitrile: A suspension of 2-(4-iodo-2-methoxy-pyridin-3-yl)-7-methyl-3H- benzimidazole-5-carbonitrile (1.8 g, 4.63 mmol) in 4 M HCI dioxane (40 mL) was heated to 80°C for 6 h and cooled to room temperature. The precipitate was filtered and dried. The crude product (1.08 g, 82%) was used for the next step without purification. LRMS (neg. ESI, (M-H)') m/z 283.
Preparation of (5)-4-(1-Benzyl-2-trityloxy-ethylamino)-3-(6-bromo-4-methyl-1H- benzimidazol-2-yl)-1H-pyridin-2-one:
Br NH, oo 5-Bromo-3-methyl-benzene-1,2-diamine: To a suspension of 4-bromo-2-methyl-6- nitro-phenylamine (20 g, 0.086 mol) in ethanol (200 mL) was added tin chloride dihydrate (49.2 g, 0.258 mol). The reaction mixture was heated to reflux for 14 h, cooled to room temperature, and concentrated in vacuo. The residue was diluted with : ethyl acetate (150 mL) and treated with triethylamine (40 mL). The resulting slurry was filtered through a pad of celite, and the filtercake was rinsed with three portions ethyl acetate (50 mL). The filtrate was washed with saturated NaHCO3, water, and brine, then dried over Na;SO, and filtered. After removal of the solvent, the residue
St was purified by flash chromatography on silica gel (30% EtOAc / hexane, then 5%
MeOH / CH,Cl,) to yield the title compound (10.26 g, 59%) as a yellow oil. 'H NMR (300 MHz, CDCl3) 6 6.77 (1H, d, J = 2.0 Hz), 6.74 (1H, d, J = 2.0 Hz), 2.16 (3H, s).
LCMS (M+H)" m/z 201. (t = 0.83 min.).
Be MeO =
TL
6-Bromo-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole: To a solution of 5-bromo-3-methyl-1,2-phenylenediamine (4 g, 19.9 mmol) in methanol (80 mL) was added 4-iodo-2-methoxy-pyridine-3-carbaldehyde (5.23 g, 19.9 mmol) in methanol (20 mL) dropwise at 0°C. The resulting slurry was stirred for 30 min at room temperature. Then iodine (2.53 g, 9.95 mmol) in methanol (20 mL) was added via a dropping funnel. After 14 h, the reaction mixture was concentrated in vacuo, diluted with 5% Na,S,03, and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and dried over Na;SO,. After removal of solvent, the residue was purified by careful flash chromatography (20% EtOAc / hexane) to yield the title compound (4.05 g, 46%) as a yellow foam. 'H NMR (300
MHz, CDCl;) 6 7.86 (1H, d, J = 5.31 Hz), 7.53 (1H, d, J = 5.3 Hz), 7.26 (2H, broad s), 3.91 (3H, s), 2.63 (3H, s). LCMS (M+H)" m/z 444 (t = 1.39 min.). 8r N A NH
TL
Cl 3-(6-Bromo-4-methyl-1H-benzimidazol-2-yl)-4-chloro-1H-pyridin-2-one: The suspension of 6-bromo-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl- 1 H- benzimidazole (4 g, 9.03 mmol) and 60 mL of 4 M HCl in dioxane was heated to 80°C for 6 h and cooled to room temperature. The precipitate was filtered and dried to yield the title compound (3.0 g, 100%) as a brown powder. The crude product was used for the next step without purification. 'H NMR (300 MHz, CD;0D) 6 7.55 (1H,
s), 742 (1H, d, J = 6.0 Hz), 7.17 (1H, 5), 6.91 (1H, d, J = 6.0 Hz), 2.55 (3H, 5). LC
MS (M+H)" m/z 338 (t = 1.33 min.). :
Br N AN
Cress
HY ay (S)-4-(1-Benzyl-2-hydroxy-ethylamino)-3-(6-bromo-4-methyl-1H-benzimidazol- 2-yl)-1H-pyridin-2-one: To a solution of 3-(6-bromo-4-methyl-1H-benzimidazol-2- yl)-4-chloro-1H-pyridin-2-one (1.42 g, 3.78 mmol) in DMF (15 mL) were added (S)- (-)-2-amino-3-phenyl-1-propanol (1.43 g, 9.45 mmol) and N-methyl morpholine (1.5 mL). The reaction mixture was heated to 80°C for 6 h and cooled to room temperature. The solvent was removed with high vacuum and the residue was purified by flash chromatography (5% MeOH / CH,Cl,) to yield the title compound (1.26 g, 74%) as a yellow foam. 'H NMR (300 MHz, CDCl3) § 6.9 — 7.2 (8H, m), 5.86 (1H, d,
J=17.1Hz),3.7-3.9 (3H, m), 2.9-3.1(2H, m), 2.57 (3H, 5s). LCMS (M+H)* m/z 453 (t =2.03 min.).
Br N A NH
Tr > (S)-4-(1-Benzyl-2-trityloxy-ethylamino)-3-(6-bromo-4-methyl-1H-benzimidazol- 2-yl)-1H-pyridin-2-one: To a solution of (5)-4-(1-benzyl-2-hydroxy-ethylamino)-3- (6-bromo-4-methyl-1H-benzimidazol-2-yl)- 1H-pyridin-2-one (0.9 g, 1.98 mmol) in
THF (30 mL), was added Cs,CO3 (1.29 g, 3.96 mmol) followed by triphenylmethyl . chloride (1.10 g, 3.96 mmol). The reaction mixture was heated to reflux for 14 h under nitrogen and then cooled to room temperature. After removal of the solvent, the residue was diluted with ethyl acetate and washed with water. The aqueous fraction was extracted with ethyl acetate and the combined organic layers were washed with water and brine, dried over Na,SQy4. After concentration in vacuo, the residue was purified by flash column chromatography (30% EtOAc / hexane) to yield the title compound (1 g, 73%) as a white solid. 'H NMR (300 MHz, DMSO-d) § 11.77 (1H, broads), 11.73 (1H, d, J = 5.2 Hz), 11.46 (1H, broad s), 7.13 — 7.54 (23H, m), 5.87 (IH, d, J =4.5Hz),4.09 — 4.14 (1H, m), 3.07 — 3.42 (4H, m), 2.54 (3H, 5). LCMS (M+H)" m/z 695 (t = 2.79 min.).
Preparation of 3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-4- chloro-1H-pyridin-2-one:
[0]
BIN
Low NO; or 1-[4-(4-Amino-3-methyl-5-nitro-phenyl)-piperazin-1-yl]-ethanone: A mixture of 4- bromo-2-methyl-6-nitro-phenylamine (5g, 21.64 mmol), 1-acetylpiperazine (4.2g, 32.46 mmol), palladium acetate (244 mg, 1.08 mmol), tri-tert-butylphosphine (440 mg, 2.16 mmol) and sodium tert-butoxide (4.2 g, 43.29 mmol) in toluene (70 mL) was heated to 100°C for 14 h under nitrogen. The reaction mixture was cooled to room temperature and diluted with EtOAc. After extraction, the combined organic layers were washed with water, brine, dried over Na;SO4. Concentration gave a brownish residue which was purified by flash column chromatography (10% MeOH / CH,Cl,) to yield the title compound (4.21 g, 70%). '"H NMR (400 MHz, CD;0D) § 7.42 (1H, d, J = 2.8 Hz), 7.23 (1H, d, J=2.8 Hz), 3.71 (2H,t,J=5.1 Hz), 3.67 2H, t,7=5.1 Hz), 3.04 2H, t,J=5.2
Hz), 2.98 (2H, t, J = 5.2 Hz), 2.24 (3H, s), 2.13 (3H, 5). LCMS (M+H)" nv/z 279 (t = 1.46 min). 0
BURN hn
NH,
1-[4-(3,4-Diamino-5-methyl-phenyl)-piperazin-1-yl]-ethanone: To 1-[4-(4-amino-3- methyl-5-nitro-phenyl)-piperazin-1-yl]-ethanone (4.5 g, 16.2 mmol) and 10% palladium ) on carbon (400 mg) were added methanol (50 mL) and acetic acid (5 mL) under nitrogen.
The reaction mixture was stirred under hydrogen atmosphere (hydrogen balloon) for 14 h.
The dark solution was filtered through a pad of celite and the filtercake was washed with methanol. Concentration of the filtrate gave the title compound (4.00 g, 100%) which was used for the next step without purification. LCMS (M+H)* m/z 207 (t = 0.41 min.).
A
Ch" oP ! 1-{4-[2-(4-Iodo-2-methoxy-pyridin-3-yl)-7-methyl-3H-benzimidazol-5-yl]-piperazin- 1-yl}-ethanone: To a solution of 1-[4-(3,4-diamino-5-methyl-phenyl)-piperazin-1-yl]- ethanone (4.00 g, 16.18 mmol) in methanol (100 mL) was added 4-iodo-2-methoxy- pyridine-3-carbaldehyde (4.25 g, 16.18 mmol). The reaction mixture was stirred at room temperature for 14 h. After concentration, the residue was purified by flash column chromatography (10% MeOH / CH,Cl,) to yield the title compound (5.25 g, 66%). 'H
NMR (400 MHz, CD;0D) 6 7.81 (1H, d, J = 5.4 Hz), 7.48 (1H, d, J = 5.4 Hz), 7.26 (1H, s), 6.85 (1H, s), 3.85 (3H, 5), 3.78 (2H, t, J = 5.0 Hz), 3.64 (2H, t, J = 5.0 Hz), 3.16 (2H, t,
J=52Hz),3.11 (2H,t,J=5.2 Hz), 2.62 (3H, s), 2.13 (3H, 5). LCMS (M+H)* m/z 492 (t = 1.71 min.). [o]
A .
L_w N NH pete
Ci 3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl}-4-chloro-1H- pyridin-2-one: To a solution of 1-{4-[2-(4-Iodo-2-methoxy-pyridin-3-yl)-7-methyl- 3H-benzimidazol-5-yl]-piperazin-1-yl }-ethanone (5.2 g, 10.6 mmol) in 4 M HCl in dioxane (60 mL) was added water (5 mL). The reaction mixture was stirred at room temperature for 14 h. Concentration of the reaction mixture gave the title compound (4.02 g, 100%) which was used for the next step without purification. LCMS (M+H)* m/z 486 (t = 1.55 min.). 3 .
Preparation of (5)-4-(1-Hydroxymethyl-2-phenyl-ethylamino)-3-(4-methyi-6- piperazin-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one: x ery
HN ay (S)-3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-4-(1- hydroxymethyl-2-phenyl-ethylamino)-1H-pyridin-2-one: To a solution of 3-[6-(4- acetyl-piperazin-1-yl)-4-methyl- 1 H-benzimidazol-2-yl]-4-chloro- 1 H-pyridin-2-one (1 g, 2.6 mmol) in DMF (10 mL) was added (S)-(-)-2-amino-3-phenyl-propanol (0.78 mg, 5.2 mmol) and N-methyl morpholine (2 mL). The reaction mixture was heated to 80°C for 12 h, cooled to room temperature and concentrated with high vacuum. The residue was purified by flash column chromatography (10% MeOH / CH,Cl,) to yield the title compound (0.90 g, 69%). 'H NMR (400 MHz, CD50D) & 7.36 (1H, s), 7.02 — 7.23 (6H, m), 6.80 (1H, s), 5.98 (IH, d, J = 7.5 Hz), 4.10 - 4.12 (3H, m), 3.67 — 3.78 (6H, m), 3.06 — 3.11 (3H, m), 2.90 (1H, dd, J = 7.8, 13.6 Hz), 2.54 (3H, 5), 2.12 (3H, 5). LCMS (M+H)" m/z 501 (t= 1.30 min.).
CL
HN,
(5)-4-(1-Hydroxymethyl-2-phenyl-ethylamino)-3-(4-methyl-6-piperazin-1-yl-1H- benzimidazol-2-yl)-1H-pyridin-2-one: To a solution of (S)-3-[6-(4-acetyl-piperazin- 1-yl)-4-methyl-1H-benzimidazol-2-yl]-4-(1-hydroxymethyl-2-phenyl-ethylamino)- 1H-pyridin-2-one (900 mg, 18 mmol) in 4 M HCI in dioxane (10 mL) was added water (1 mL). The reaction mixture was heated to 80°C for 14 h and cooled to room temperature. Concentration with high vacuum gave the title compound (0.83 g, 100%) which was used for the next step without purification. LCMS (M+H)* m/z 459 (t = 1.13 min.).
Preparation of 2-(4,6-Dichloro-pyrimidin-5-yl)-6-imidazol-1-yl-4-methyl-1H- benzimidazole:
H “ =N rh cl 4,6-Dichloro-pyrimidine-5-carbaldehyde: DMF (7 mL, 0.09 mol) was added to
POC]; (21 mL, 0.23 mol) at 0°C. The reaction mixture was stirred at room temperature for 0.5 h. 4,6-Dihydroxy-pyrimidine-5-carbaldehyde (5 g, 0.045 mol) was added in small portions. The reaction mixture was heated to 90°C for 6 h and cooled to room temperature. A large excess of crushed ice was added to the reaction mixture very slowly under ice-bath. The mixture was extracted with CH,Cl,. The combined organic layers were washed with water, brine, and dried over Na,SOy. After concentration, the residue was purified by column chromatography (20% EtOAc / hexane) to yield the title compound (4 g, 50%). 'H NMR (400 MHz, CDCls) 6 8.91 (1H, s), 7.87 (1H, s). LRMS (M+H)" m/z 177.
Chott Ben
CL
Cl 2-(4,6-Dichloro-pyrimidin-5-yl)-6-imidazol-1-yl-4-methyl-1H-benzimidazole: To a solution of 5-imidazol-1-yl-3-methyl-benzene-1,2-diamine (180 mg, 0.96 mmol) in methanol (4 mL) was added a solution of 4,6-dichloro-pyrimidine-5-carbaldehyde ( 183 mg, 0.96 mmol) in methanol (1 mL). The reaction mixture was stirred at room temperature for 14 h. After concentration, the residue was purified by flash column chromatography (5% methanol / CH,Cl,) to yield the title compound (180 mg, 55%).
LCMS (M+H)' m/z 344 (t = 1.31 min.).
Procedure for the Preparation of 2-Amino-4-Fluoro-6-methyl nitrobenzene:
F F
[0]
Y [o} (o] t 2-(3,5-Difluoro-2-nitro-phenyl)-malonic acid di-tert-butyl ester: To a suspension of
NaH (54.6g, 60%, 1.365 mol) in 600mL of DMF was added di-r-Butyl malonate (118g, 0.546 mol) at 0°C and stirred for 30 min. 2,4,6 trifluoronitrobenzene was added as a solution in 400 mL of DMF (75 g, 0.42mol) over 3 hours and the solution stirred at ambient temperature for 12 hours. The reaction mixture was extracted with ethyl acetate (3X’s). The ethyl acetate was washed with water (3X’s) and with brine and dried over MgSO, and concentrated to give 62 g of crude product. LCMS [M+Na] - 396; 'H NMR (500MHz, DMSO) & 7.81 (m, 1H), 7.27 (m, 1H), 5.00 (s, 1H), 1.41 (m, 18H). £ NH, ye 0
Y [o] 0 1 2-(3-Amino-5-fluoro-2-nitro-phenyl)-malonic acid di-tert-butyl ester: To the crude 2-(3,5-Difluoro-2-nitro-phenyl)-malonic acid di-ferz-butyl ester (62g, 0.42 mol) was added 700 mL of 2M ammonia in methanol in a pressure bottle. The vessel was sealed and heated to 85°C for 18 hours. The reaction mixture was cooled and the } vessel opened carefully and the methanol solution concentrated to provide 140 g of crude material. LCMS [M+Na] - 393; 'H NMR (500MHz, DMSO) 6 6.76 (dd,
Claims (71)
1. A compound according to formula I R3 R? K Y Ww yeuaadt R* N X RS R® TR’ I oe its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and oo solvates thereof: wherein X is selected from the group consisting of N, C, C,-C; alkyl, C,-C; alkyl substituted with one or more R’ and a direct bond; Y is selected from the group consisting of O and S; W is selected from the group consisting of N, C, O, and S; provided that if W is O or S, R’ is absent; R!, RL, R® RY R®, R’ R% R® are each independently selected from the group So consisting of H, Cy alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, OR%, NO,, OH, SR®, NR¥R®, CN, CO,R®’, CONR®R®', OCONR®R®, NR®CONR®R®, NR¥SO,R®' , SO,NRPR®!, CONRH)NR®*R®!, aryl, heteroaryl, k (CH,).0R®, (CH,).NR*R®, (CH,),SR¥, (CH,), aryl, (CHa), heteroaryl, , (CHz), heterocycloalkyl, NH-Z-aryl, and NH-Z-heteroaryl; whereinn is 1 to 3; RS is H, C,.s alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, OR%, NO,, OH, SR¥®, NR*R®', CN, CO,R®, CONR®R®', OCONR¥R®, NRE2CONR®R®!, NR®SO,R® , SO,NR¥R®", CONRS2NR®R', (CH,),0R®, (CH2):NR®R®, (CH,),SR®, (CH), aryl, (CHy), heteroaryl, (CHy), heterocycloalkyl, NH- Z-aryl, and NH-Z-heteroaryl provided that R® is not Hif Y is S; and 221 AMENDED SHEET
I ree IPEA/US : LER NR SR ENTE a Ed EE AMENDED SHEET R¥isH, C6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, NO, OH, SR®, NR*R® , CN, CO,R®, CONR*R®', OCONR*R"", NRPCONR®RS!, NR®SO,R®! | SO;NR®R®!, C(NRHNR®R®!, (CH), OR, . (CH2).NR*R®, (CH,),SR®, (CH,), aryl, (CHa), heteroaryl, , (CHa), heterocycloalkyl, NH-Z-aryl, and NH-Z-heteroaryl; : Z is selected from the group consisting of C; — C, alkyl, alkenyl, and alkynyl chain; Z having one or more hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, NR®SO,R® groups; Z optionally incorporating one or more groups selected from the group consisting of CO, CNOH, CNOR®, CNNR® , CNNCOR® and CNNSO,R*‘ and : R®, and R¥ are independently selected from the group consisting of H, alkyl, oo alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, and alkyl-R* wherein R* is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, NR? 'COOR?!, - NR¥C(O)R?, -NRSO,R*, -C(O)NR**R®, heteroaryl or heterocycloalkyl; and R* and R¥! are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R® . 221-1 AMENDED SHEET
To _, AMENDED SHEET IPEA/US ] : foe ELE EE TR RRR EE EE
2. "The compound according to claim 1 wherein Rr R’, R®and R® are H; R? and R*are Hor F; Y is O; ‘ X is selected from the group consisting of N and CH; Wis N; RS is selected from the group consisting of H, methyl, ethyl, isopropyl, secondary butyl, cyclopropyl, F, and CFs; R® is selected from the group consisting of H, 2-aminomethylpyrndine, NHCH,CH(OH)Ph, NHCH,CH(OH)(3-Cl-Ph), NHCH,CH(OH)(3-Br-Ph), NHCH,CH(OH)(3-Br-4-OMe-Ph), NHCH(CH,OH)CH,Ph, NHCH,CH(OH)aryl, and NHCH(CH,OH)CHaaryl; and R? is selected from the group consisting of OR®, C(NH)NHR®, C(O)NHR® imidazole, imidazoline, tetrahydropyrimidine, piperazine, morpholine, homomorpholine, piperidine, pyrrolidine, homopiperazine and amino; wherein R® is selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, and alkyl-R* wherein R? is hydrogen, alkenyl, hydroxy, thiol, thioalkoxy, alkoxy, thioalkoxy, halo, cyano, sulfoxy, sulfonyl, “NR¥COOR’, - NR*C(O)R? l -NR¥SO,R?, -C(O)NR® °R*' or a heteroaryl or heterocycloalkyl; and Ryo and Rs, are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R? .
3. The compound according to claim 2 wherein R? is —OR® and R% is alkyl, or ~ alkyl-R*®, wherein 222 AMENDED SHEET
R” is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR**COOR?', -NR*C(O)R*!, -NR*’SO,R*, - C(O)NR*R3! heteroaryl! or heterocycloalkyl; and Rip and Rj are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R*. 4, The compound according to claim 3 wherein R% is methyl, -(CH,),CH,OH, or -(CH2)sCH,N(CH,CH;);0, and nis 0, 1, or 2.
5. The compound according to claim 3 wherein R* is morpholine, 0 L (0) Pate AR = _ 4 3 = + 8 0 N N NR Ras Ra 4 =N 3 N-N ~N N- NEE Gy Ge Py ee 0 R o 0 Ag N\ le) —Uk 31 31 wherein R*is hydrogen, alkyl, or substituted alkyl.
6. The compound according to claim 2 wherein R? is piperazine, homopiperazine, 3-methylpiperazine, or 3,5-dimethylpiperazine being optionally substituted at the 4-N position with a compound selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkyl-R*,-C(O)-R'?, or -CO;R'® wherein R'” is hydrogen, alkyl, aryl, alkyl-R?*, amino or aryl; and RZ is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, cyano, halo, sulfoxy, sulfonyl, arylsulfonyl, - NR*COOR?, -NR*C(O)R*, -NR¥*SO,R*, -C(O)NR*R?!, heteroaryl or heterocycloalkyl; and R* and RY are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%.
TT. The compound according to claim 6 wherein said piperazine is substituted . with methyl, ethyl, CH,-cyclopropyl, hydroxyethyl, 2-dimethylaminoethyl, 2- diethylaminoethyl, 2-aminoethyl, 2-methylaminoethyl, 2-ethylaminoethyl, methoxyethyl, ethoxyethyl, morpholine, and morpholinylethyl.
8. The compound according to claim 2 wherein R? is an amino group selected from the group consisting of hydroxyalkylamino, aminoalkylamino, dialkylaminoalkylamino, and heterocycloalkylalkylamino.
S
9. The compound according to claim 8 wherein said amino is selected from the group consisting of NHCH,CH,OH, NMeCH,CH,0H, NEtCH,CH,0H, NHCH,CH;NH;, NMeCH,CH;,NH,, NEtCH,CH,NH,;, NHCH,CH;NMe,, NMeCH,CH;NMe,, NEtCH,CH,NMe,, NHCH,CH,;NEt;, NMeCH,CH;,NEt,, NEtCH,CH,NEt,, NHCH,CH,N(CH,CH,),0, NMeCH,CH,N(CH,CH>),0, and NEtCH,CH,;N(CH,CH,)-0.
10. The compound according to claim 2 wherein R? is piperidine, optionally substituted with hydroxy, thiol, amino, alkylamino, dialkylamino, alkoxy, thioalkoxy, 1,3 dioxolane, 1,3 dioxane, -NHC(O)R" , -NHCO,R", wherein R'is hydrogen, alkyl, aryl or alkyl-R® wherein R? is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR¥*COOR?!, -NR*c(O)RY, -NR¥SO,R*!, - C(O)NR RY, heteroaryl or heterocycloalkyl; and R*® and R*' are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R® .
11. The compound according to claim 2 wherein R’ is morpholine, thiomorpholine, sulfoxymorpholine, sulfonylmorpholine, or homomorpholine, or a substituted morpholine, thiomorpholine, sulfoxymorpholine, sulfonylmorpholine, or homomorpholine.
12. The compound according to claim 11 wherein said morpholine, thiomorpholine, sulfoxymorpholine, sulfonyl morpholine, or homomorpholine is substituted with hydroxy, thiol, amino, alkylamino, dialkylamino, alkoxy, thioalkoxy, alkyl-R® : -NHC(O)R'’, -NHCO,R", wherein R'® is hydrogen, alkyl, aryl or alkyl-R* wherein R> is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, cyano,
sulfoxy, sulfonyl, -NR*®*COOR? | -NR*C(O)R?*!, -NR¥SO,R?!, -C(O)NR*R?, heteroaryl or heterocycloalkyl; and R*® and RY are, independently, hydrogen, alkyl, cycloalkyl, or alkyl-R%. . 5 13. The compound according to claim 2 wherein R? is (CH,),-morpholine or (CHy),- piperazine, wherein n is 1 to 3.
14. The compound according to claim 2 wherein R? is an optionally substituted N- tetrahydropyrimidine or N-imidazoline.
15. The compound according to claim 14 wherein at least one of said substituents is alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cyanoalkyl, carboxyl, or carboxamide.
16. The compound according to claim 2 wherein R’ is pyrrolidine.
17. The compound according to claim 2 wherein said pyrrolidine is selected from the group consisting of 3-hydroxyl pyrrolidine, 3- alkoxy pyrrolidine, and 3- alkylamino pyrrolidine, 3-dialkylamino pyrrolidine.
18. The compound according to claim 2 wherein R® is selected from the group consisting of H, 2-aminomethylpyridine, NHCH,CH(OH)aryl, and NHCH(CH,;OH)CHsaryl.
19. The compound according to claim 18 wherein said aryl is an optionally substituted phenyl.
20. The compound according to claim 19 wherein said phenyl is substituted with a Br, Cl, F, alkoxy or-NHSO,CH3.
21. The compound according to claim 19 wherein said substituent is 3-Br, 3-Cl or
3-F.
22. The compound according to claim 19 wherein said substituent is 4-F or 4- methoxy.
23. The compound according to claim 19 wherein R®is “NH “SNH “SNH HO HO HO < | Riz < | 17 Ry7
[0] \ NR4o " NR (o] AN wo NH “ HN ~~ HO
OR . Q Far Ryz7 r he NRao =r " wherein R'is H, Br, Cl, or F and R* is H or alkyl.
24. A compound having the formula: Riz o™ H ©O AN N NH Rig ) NN 7 HN HOw Riz
10 . Rig Rig wherein R'? and R" are, independently, hydrogen, alkyl, or alkyl-R* wherein R? is hydrogen, hydroxy, thiol, alkenyl, amino, alkoxy, thioalkoxy, halo, cyano, sulfoxy, sulfonyl, -CO.H, -C(O)NR*R?', -NR**SO,R*', -NR*C(O)R*, - NR¥*C(O)ORY, heteroaryl or heterocycloalkyl; R'7, R'® and R" are, independently, hydrogen, halogen, or alkoxy, or R'® and R'® together form a heterocycloalkyl or heteroaryl group; and R*and R*' are, independently, hydrogen, alkyl, or alkyl-R%.
25. The compound according to claim 24 wherein R* is morpholine, 0) iN . N N N N=n 9 oo [l — J —N ey N_J — J Non TRE Tew N N NR Ras Ras ’ <N 31 N-n =N N- —N % JY 4 T % — or N EU Un Ue 31 31 5 wherein R¥is hydrogen, alkyl, or substituted alkyl.
26. The compound according to claim 24 wherein R'%is hydrogen, methyl, hydroxymethyl, methoxymethyl, CH,F, CH,CN, CO,H, or -CONR*’R*' wherein R* and R*' are, independently, hydrogen, or alkyl-R* .
27. The compound according to claim 24 incorporating the side chain “nn SNH SNH HO HO HO R Rez Ry7 " 0 NRyo [o] “NH HN ~ HO HO vo NH OR R PE 17 1 Ry7 o Ruy o “ \=N wherein R* is hydrogen or alkyl, and R™ hydrogen or halogen.
28. The compound according to claim 24 wherein R'?and R” are H; R'is Br, F, or CI; R'%is methoxy or fluoro; and RY? is H; or R'® and R" together form 4-0, 5 dihydrofuranyl. :
29. The compound according to claim 24 wherein R'?and R'3 are methyl; R" is Br, For Cl, R% is hydrogen or methoxy; and R'is H.
30. A compound having the formula fie . ew H Q CGA N HN HOw Ry7 Ryo Ris wherein R;s is hydrogen, alkyl, aryl, or -alkyl-R*, wherein R? is is-hydrogen, hydroxy, thiol, alkenyl, amino, alkoxy, thioalkoxy, halo, cyano, sulfoxy, sulfonyl, -NR*COOR?, -NR*¥C(O)R?, -NR*’SO,R*, -C(O)NR*R*', heteroaryl or heterocycloalkyl; R'® is each independently hydrogen or methyl; R', R'® and R" are, independently, hydrogen, halogen, or alkoxy; or R'® and RY together form a heterocycloalkyl! or heteroaryl group; and R*® and R*' are, independently, hydrogen, alkyl or alkyl-R% .
31. The compound according to claim 30 wherein Ris morpholine, thiomorpholine, Oo 0 N N=p N N Ra Nn ; i v= ~<A, J oh, — or —l
32. The compound according to claim 30 incorporating the sidechain
NH NH NH HO HO HO = R47 \ Ry7 Riz 0 NRso NR4o 4) NH NH NH HO HO HO OR R o Rs 0 Riz NRgp i NR \=N 0 wherein R% is hydrogen or alkyl and RY hydrogen or halogen.
33. The compound according to claim 30 wherein R'” is hydrogen, methyl, ethyl, or (CH2).CH>-R® wherein R? is OH, OMe, F, CN, CF3, SOCH3 or SO,CHj3, wherein n isOor 1.
34 The compound according to claim 30 wherein RY is cyanoethyl, hydroxyethyl, CH,CH,SOCH;, CH,CH,CH,F, CH,CH,CH,CN, or CH,CH,CF;, R'® and R" are H;R" is Br, or Cl; and Rg is hydrogen or methoxy.
35. A compound having the formula: pil Rie Ris JQ! H (0) Rig N NH / HN HOw Riz Rg Ris wherein RY is hydrogen, alkyl, aryl or alkyl-R*” :
R% is hydrogen, hydroxy, thiol, alkenyl, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR**COOR?', -NR*C(O)R*', -NR*’SO,R?!, - C(O)NR*R*, heteroaryl or heterocycloalkyl; R'® is each independently hydrogen or methyl; R' R'®and R' are, independently, hydrogen, halogen, or alkoxy, or R'® and rR" together form a heterocycloalkylor heteroaryl group; and R* and R* are, independently, hydrogen, alkyl, cycloalkyl or alkyl-R%.
36. The compound according to claim 35 wherein R* is morpholine, thiomorpholine, (o] L N N N Nan — O _ 3 —N —_J | : vs N_ NJ Non Ne \=N N N No _R Ra Raq SSN 31 N-n nN N- —N <I —~« J a a or N NT 0 Rj, [0] 0g, \_-0 —\Nh wherein R* is hydrogen, alkyl, or substituted alkyl.
37. The compound according to claim 35 incorporating the sidechain “am SNH “SNH ) ) HO R R R J 17 \ NA 17 Neo 17
[0] “aH HN” . HO HO NH HO OR fo} Riz Rey a : NR r 0 NR i v wherein R* is hydrogen or alkyl and R'7 hydrogen or halo.
38. The compound according to claim 35 wherein R"® is hydrogen or methyl; R" } 5 is bromo, chloro or fluoro; R'® is hydrogen or methoxy; and Ris hydrogen .
39. A compound having the formula O Ry EEN H O R, AN N NH 4 CL «J HN How { Ry7 : Rig Rig wherein Ris is hydrogen, alkyl, or, -alkyl-R% R R” is hydrogen, hydroxy, thiol, alkenyl, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR*COOR?, -NR*C(0)R*, -NR¥SO,R* | -C(O)NR*’R*, heteroaryl or heterocycloalkyl; R' is each independently hydrogen or methyl; R", R'® and R" are, independently, hydrogen, halogen, or alkoxy; or R'®and R'’ together form a heterocyclo or heteroaryl group; and R¥ and R* are, independently, hydrogen, alkyl, cycloalkyl or alkyl-R%® .
40. The compound according to claim 39 incorporating the sidechain
“im “NH NH HO | | HO Ry7 R R 7 \ NRgg i NRgo o “NH HN" HO HO TNH HO x OR C Riz Riz R ye NRe o_T 17 wherein R* is hydrogen or alkyl and RY hydrogen or halo.
41. The compound according to claim 39 wherein R" is hydrogen, methyl, ethyl, or -(CHy),CH,-R® wherein nis 0, 1, or 2; and R” is OH, OMe, F, CN, CF;, SOCH; or SO,CHj3, -NR*COR?', -NR*COOR? -NR¥S0,RY, -C(O)NR*R?, or has the formula: 0 * . N N N N=nN NO NT —N —N_J —N N N NL _R Rai Ra , =N 31 N-n =N N-n —N C1. —~ 71 7 1 or n N= 8 Ry © A Ra wherein R*® is hydrogen, alkyl, or substituted alkyl.
42. The compound according to claim 39 wherein R" is ethyl, methoxyethyl, CH,CH,F, or CH,CH,CN; R'7 is bromo or chloro; R'is methoxy or hydrogen; and R"is hydrogen.
43. A compound having the formula: H H _ Rison AN I. I TO H OQ o N N NH : o N N NH > ay jo \_/ N HN HN OR HO!" HOM Rs Riz Rie Ria Rip Rig wherein Ris is hydrogen, alkyl, aryl, or -alkyl-R%>; R? is hydrogen, hydroxy, thiol, alkenyl, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR*COOR?, -NR¥C(O)R?!, -NR*SO,R’ '- C(O)NR*R®!, heteroaryl or heterocycloalkyl; R',R"® and R" are, independently, hydrogen, halogen, or alkoxy; or R'® and R' together form a heterocyclo or heteroaryl group; and R* and R¥ are, independently, hydrogen, alkyl, cycloalkyl or alkyl-R%.
44. The compound according to claim 43 wherein RY is «(CH)nCH,R® nis 0, 1, 2 or 3 and R% is OH, OMe, F, CN, CFs, SOCH3 or SO,CHs , -NR*COOR?, - NR¥C(O)R*, -NR*SO,R*, -C(O)NR’'R* or has the formula: (0) L N N N Nzn NO gS —N —N_] —N Ng NI NJ Neon Ne \=N Ra, Ra Ney — 0 Ast a eS N-n —N _ J} T 4 ( [} or i N= 0g, © 0p, Wa ) 20 wherein R*is hydrogen, alkyl, or substituted alkyl.
45. The compound according to claim 43 wherein R'® is methyl, ethyl, CH,F, methoxyethyl, CH,CH,F, or CH,CH,CH,SOCH3; R'” is bromo; R'® is hydrogen, methoxy, or fluoro; and R'? is H.
46. The compound according to claim 45 incorporating the sidechain “ni NH SNH HO HO HO R47 Ry7 Ry7 o \ NRg4o NRyo oO “nH ~~ HO ml NH HO HO OR 0 Ry7 R )r~NRa in 7 lo) Riz pd 40 \=N wherein R*® is hydrogen or alkyl, and R'is hydrogen or halo.
47. A compound having the formula: Rys Ris Rs a Th 1) 4H R Res 1) H O N N NH N N NH CHS a oc HN HN HOw . or HO Ry? Rez Rio Ris Rig Rig wherein each R'? is independently hydrogen, alkyl, aryl, or -alkyl-R* ; )
R® is hydrogen, hydroxy, thiol, alkenyl, alkoxy, thioalkoxy, amino, halo, cyano, sulfoxy, sulfonyl, -NR®COOR?', -NR¥C(O)R*!, -NR*SO,R?, - C(O)NR*R¥ heteroaryl or heterocycloalkyl; R',R'® and R" are, independently, hydrogen, halogen, or alkoxy; or R'® and i 5s R'" together form a heterocyclo or heteroaryl group; and R*® and R* are, independently, hydrogen, alkyl, cycloalkyl or alkyl-R%.
48. The compound according to claim 1 selected from the group consisting of : A compound according to claim 1 having the formula: (S)-4-(2-Hydroxy-1-phenyl-ethylamino)-3-(6-imidazol- 1-yl-4-methyl-1H- benzimidazol-2-yl)-1H-pyridin-2-one; ()-4-[2-Hydroxy-2-(3-iodo-phenyl)-ethylamino]-3-(6-imidazol-1-yl-4-methyl- 1H- benzimidazol-2-yl)- 1H-pyridin-2-one; (+)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-(6-imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)-1H-pyridin-2-one; (£)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)-1H-pyridin-2-one; (5)-4-[2-(2-Chloro-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol-1-yl-4- methyl- 1 H-benzimidazol-2-yl)-1H-pyridin-2-one; (S)-4-[2-(3-Chloro-phenyl)- 1-hydroxymethyl-ethylamino]-3-(6-imidazol-1-yl-4- methyl- 1H-benzimidazol-2-yl)-1H-pyridin-2-one; (S)-4-[2-(4-Chloro-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol- 1-yl-4- methyl- 1H-benzimidazol-2-yl)- 1H-pyridin-2-one; (S)-4-[2-(2-Bromo-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol-1-yl-4- methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; (8)-4-[2-(3-Bromo-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol-1-yl-4- methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; (+)-4-(1-Hydrox ymethyl-2-pentafluorophenyl-ethylamino)-3-(6-imidazol-1-yl-4- methyl- 1 H-benzimidazol-2-yl)-1H-pyridin-2-one; (S)-4-(1-Hydroxymethyl-2-pyridin4-yl-ethylamino)-3-(6-imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)- 1H-pyridin-2-one;
(5)-4-[1-Hydroxymethyl-2-(2-naphthalenyl)-ethylamino]-3-(6-imidazol-1-yl-4- methyl-1H-benzimidazol-2-yl)- 1 H-pyridin-2-one; 3-(6-Imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-(pyridin-2-ylmethoxy)- 1H- pyridin-2-one; ($)-4-[2-(3-Bromo-phenyl)-2-fluoro-ethylamino}-3-(6-imidazol-1-yl-4-methyl- 1 H- benzimidazol-2-yl)- 1H-pyridin-2-one; (8)-2-[4-(1-Hydroxymethyl-2-phenyl-ethylamino)-2-oxo-1,2-dihydro-pyridin-3-yl]-7- methyl-3H-benzimidazole-5-carbonitrile; (£)-2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-2-oxo-1,2-dihydro-pyridin-3- yl}-7-methyl-3H-benzimidazole-5-carbonitrile; (S5)-2-{4-[2-(3-Chloro-phenyl)- 1-hydroxymethyl-ethylamino]-2-oxo-1,2-dihydro- pyridin-3-yl}-7-methyl-3H-benzimidazole-5-carbonitrile; (2)-2-{4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydrox y-ethylamino]-2-oxo-1,2-dihydro- pyridin-3-yl}-7-methyl-3H-benzimidazole-5-carbonitrile; (%)-2-{4-[2-(3-Fluoro-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro-pyridin-3- yl}-7-methyl-3H-benzimidazole-5-carbonitrile; ()-2-{4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-2-oxo- 1,2-dihydro-pyridin-3- yl}-7-methyl-3H-benzimidazole-5-carbonitrile; ($)-2-[4-(2-Hydroxy-2-phenyl-ethylamino)-2-oxo-1,2-dihydro-pyridin-3-yl]-7- methyl-3H-benzimidazole-5-carbonitrile; (+)-3-(1H-Benzimidazol-2-yl)-4-[2-(3-bromo-phenyl)-2-hydrox y-ethylamino]- 1 H- pyridin-2-one; (8)-3-(1H-Benzimidazol-2-yl)-4-(1-hydrox ymethyl-2-phenyl-ethylamino)- 1 H- pyridin-2-one;
. 25 (})-3-(1H-Benzimidazol-2-yl)-4-[2-(3-bromo-4-methoxy-phenyl)-2-hydroxy- } ethylamino]-1H-pyridin-2-one; (5)-4-{2-[4-(1-hydroxymethyl-2-phenyl-ethylamino)-2-oxo- 1,2-dihydro-pyridin-3- yl]-7-methyl-3H-benzimidazol-5-yl }-piperazine- 1-carboxylic acid isopropylamide; (8)-4-{2-[4-(1-hydroxymethyl-2-phenyl-ethylamino)-2-oxo-1,2-dihydro-pyridin-3-y1]-7- methyl-3H-benzimidazol-5-yl}-piperazine-1-carboxylic acid ethylamide; ) (5)-4-(1-Hydroxymethyl-2-phenyl-ethylamino)-3- {4-methyl-6-[4-(1-phenyl-methanoyl)- piperazin-1-yl]- 1H-benzimidazol-2-yl }- 1H-pyridin-2-one;
(5)-4-(1-Hydroxymethyl-2-phenyl-ethylamino)-3-[6-(4-isopropyl-piperazin-1-yl)-4- methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one;
(S)-3-[6-(4-Benzyl-piperazine- 1-yl)-4-methyl- 1H-benzimidazoi-2-yl]-4-(1- hydroxymethyl-2-phenyl-ethylamino)-1H-pyridin-2-one;
()-3-[6-(4-Acetyl-piperazine-1-yl)-4-methyl- 1H-benzimidazol-2-yl]-4-{2-(3-chloro- phenyl)-2-hydroxy-ethylamino]- 1 H-pyridin-2-one; (£)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-piperazin-1-yl- 1H- benzimidazol-2-yl) -1H-pyridin-2-one; (+)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-[6-(4-isopropyl-piperazine- 1-yl)-4-
methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one; (5)-6-(1-Hydroxymethyl-2-phenyl-ethylamino)-5-(6-imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)-3H-pyrimidin-4-one;
(85)-2-{6-Chioro-5-(6-imidazol- 1-yl-4-methyl- 1 H-benzimidazol-2-yl)-pyrimidin-4- ylamino]-3-phenyl-propan-1-ol;
(8)-4-(2-Hydroxy-2-phenyl-ethylamino)-3-(6- imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)-1H- pyridin-2-one; (R)-4-(2-Hydroxy-2-phenyl-ethylamino)-3-(6-imidazol- 1-yl-4-methyl-1H- benzimidazol-2-yl)- 1 H-pyridin-2-one; (1S,2R)-4-(1-Hydroxy-indan-2-ylamino)-3-(6-imidazol-1-yl-4-methyl-1H-
benzimidazol-2-yl)- 1H-pyridin-2-one; (1)-4-[2-Hydroxy-2-(3-hydroxy-phenyl)-ethylamino]-3-(6-imidazol- 1-yl-4-methyl- 1H-benzimidazol-2-yl)- 1H-pyridin-2-one; (8)-4-(2-Hydroxy-2-pyridin-2-yl-ethylamino)-3-(6-imidazol-1-yl-4-methyl-1H- benzimidazol-2-yl)- 1H-pyridin-2-one;
(¥)-N-(3-{1-Hydroxy-2-[3-(6-imidazol-1-yl-4-methyl- 1 H-benzimidazol-2-yl)-2-0xo0- 1,2-dihydro-pyridin-4-ylamino]-ethyl } -phenyl)-methanesulfonamide; (+)-4-[2-(3-Fluoro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol- 1-yl-4-methyl- 1 H- benzimidazol-2-yl)-1H-pyridin-2-one;
oo (2)-4-[2-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4- methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; (S)-4-[2-(3-Fluoro-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol- 1 -yl-4- methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one;
(+)-4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino]-3-(6-imidazol-1-yl- 1 H- benzimidazol-2-yl)-1H-pyridin-2-one; (£)-4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino}-3-(6-imidazol- 1-yl-4- methyl-1H-benzimidazol-2-yl)- | H-pyridin-2-one;
(8)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl- 1 H- benzimidazol-2-yl)-1H-pyridin-2-one;
(S)-4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino]-3-(6-imidazol- 1-yl-4-methyl-1 H- benzimidazol-2-yl)-1H-pyridin-2-one; (R)-4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino]-3-(6-imidazol- 1-yl-4-methyl- 1 H-
benzimidazol-2-yl)-1H-pyridin-2-one; (#)-4-[2-(3-Chloro-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4- methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one;
(+)-(2-Chloro-4-{ 1-hydroxy-2-[3-(6-imidazol-1-yl-4-methyl- 1 H-benzimidazol-2-yl)- 2-0x0-1,2-dihydro-pyridin-4-ylamino]-ethyl } -phenyl)-carbamic acid methyl ester;
(S)-4-(1-Hydroxymethyl-2-phenyl-ethylamino)-3-[4-methyl-6-(4-methyl-piperazin-1- yl)-1H-benzimidazol-2-yl]- 1H-pyridin-2-one;
(5)-4-(1-Hydrox ymethyl-2-phenyl-ethylamino)-3-[4-methyl-6-(4-n-butyl-piperazin-1-yl)- 1H-benzimidazol-2-yl}-1H-pyridin-2-one; (5)-3-{6-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-4-methyl- 1H-benzimidazol-2-yl } -4-(1-
hydroxymethyl-2-phenyl-ethylamino)- IH-pyridin-2-one;
($)-4-{2-[4-(1-Hydrox ymethyl-2-phenyl-ethylamino)-2-oxo-1,2-dihydro-pyridin-3- yl]-7-methyl-3H-benzimidazol-5-yl } -piperazine-1-carboxylic acid amide; (£)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-piperazin-1-yl-1H- benzimidazol-2-yl)-1H-pyridin-2-one;
(%)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-[6-(4-ethyl-piperazin-1-yl)-4- _.. methyl- 1H-benzimidazol-2-yl]- 1H-pyridin-2-one;
()-4-[2-(3-Chloro-phenyl)-2-hydroxy-eth ylamino]-3- {6-[4-(2-hydroxy- ethyl)piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl }- 1Hpyridin-2-one, (+)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-(4-methyl-6-morpholin-4-yl-
1H-benzimidazol-2-yl)-1H-pyridin-2-one; ; (+)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin- 4-yl-1H-benzimidazol-2-yl)- 1H-;
(¥)-4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6- morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; (3)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3- { 6-[4-(2-hydroxy-ethyl)- piperazin- 1-yl]-4-methyl-1H-benzimidazol-2-yl }- 1H-pyridin-2-one;
. S (3)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-piperazin- 1-yl-1H-benzimidazol-2-yl }-1H-pyridin-2-one; (1)-4-[2-(3-Bromo-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-piperazin- 1-yl-1H-benzimidazol-2-yl }- 1H-pyridin-2-one; (3)-3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl}-4-[2-(3-bromo- phenyl)-2-hydroxy-ethylamino]-1H-pyridin-2-one; (S)-4-(1-hydroxymethyl-2-phenyl-ethylamino)-3-[4-methy}-6-(2-morpholin-4-yl- ethylamino)- 1 H-benzimidazol-2-yl]-1H-pyridin-2-one; (#)-6-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-5-(6-imidazol- 1-yl-4-methyl- 1 H- benzimidazol-2-yl)-3H-pyrimidin-4-one; (£)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[6-(1-hydroxy- 1-methyl-ethyl)- 4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one; (+)-3-(6-Aminomethyl-4-methyl-1H-benzimidazol-2-yl)-4-[2-(3-chloro-phenyl)-2- hydroxy-ethylamino]-1H-pyridin-2-one; (#)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(6-hydrox ymethyl-4-methyl- 1H-benzimidazol-2-yl)-1H-pyridin-2-one; (S)-4-(1-Benzyl-2-hydroxy-ethylamino)-3-(4-methyl-6-morpholin-4-yl- 1H- benzimidazol-2-yl)- 1H-pyridin-2-one; and (8)-4-(1-Benzyl-2-hydroxy-ethylamino)-3-(4-methyl-6-piperidin-1-yl-1H- benzimidazol-2-yl)- 1H-pyridin-2-one;
49. The compound according to claim 1 selected from the group consisting of: (S)-4-(1-Benzyl-2-hydroxy-ethylamino)-3-(4-methyl-6-piperidin-1-yl-1H- benzimidazol-2-yl)- 1H-pyridin-2-one; 4-[2-(3-Chloro-4-methylsulfanyl-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6- : 30 piperazin-1-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one; 4-[2-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-piperazin-1- yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one;
3-[4-(2-{4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino]-2-0xo- 1,2-dihydro-pyridin- 3-yl}-7-methyl-3H-benzoimidazol-5-yl)-piperazin- 1-yl]-propionitrile; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-methanesulfonyl-ethyl)- piperazin-1-yl]-4-methyl- 1 H-benzoimidazol-2-yl }- 1 H-pyridin-2-one; 3-[4-(2-{4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydrox y-ethylamino]-2-oxo-1,2- } dihydro-pyridin-3-yl}-3H-benzoimidazol-5-yl)-7-methyl-piperazin-1-yl]- propionitrile; 4-(2-{4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino]-2-oxo-1,2-dihydro-pyridin-3- yl }-7-methyl-3H-benzoimidazol-5-yl)-piperazine- 1 -carboxylic acid 2-fluoro-ethyl ester, 4-(2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro-pyridin-3- yl }-7-methyl-3H-benzoimidazol-5-yl)-piperazine- | -carboxylic acid 2-methoxy-ethyl ester; 4-(2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro-pyridin-3-
yl}-7-methyl-3H-benzoimidazol-5-yl)-piperazine-1-carboxylic acid tert-butyl ester; 4-(2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro-pyridin-3- yl }-7-methyl-3H-benzoimidazol-5-yl)-piperazine-1-carboxylic acid prop-2-ynyl ester; 4-(2-{4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro- pyridin-3-yl}-7-methyl-3H-benzoimidazol-5-yl)-piperazine- 1-carboxylic acid tert-
butyl ester;
(S)-4-(2-{4-[2-(3-Bromo-4-methox y-phenyl)-2-hydrox y-ethylamino}-2-oxo-1,2- dihydro-pyridin-3-yl }-7-methyl-3H-benzimidazol-5-yl)-piperazine- 1-carboxylic acid ethyl ester;
4-[2-(3-Chloro-4-methox y-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(3-fluoro-propyl)-
piperazin-1-yl]-4-methyl- 1H-benzoimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3- 6-[4-(2-fluoro-ethyl)-piperazin- 1- yl]-4-methyl- 1H-benzoimidazol-2-yl}-1H-pyridin-2-one; 4-[2-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino}-3-{6-[4-(3-fluoro-propyl)- piperazin-1-yl]-4-methyl- 1 H-benzoimidazol-2-yl } - |H-pyridin-2-one;
4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(3-fluoro-propyl)- piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl } -1H-pyridin-2-one;
4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-{4-methyl-6-[4-(3,3,3-trifluoro- propyl)-piperazin-1-yl]-1H-benzoimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(3-fluoro-propyl)-piperazin- 1-yl]-4-methyl-1H-benzoimidazol-2-yl }-1H-pyridin-2-one;
. 5 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{4-methyl-6-[4-(3.4,4-trifluoro-but- 3-enyl)-piperazin-1-yl]-1H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(3-fluoro-2-hydroxy-propyl)- piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2-hydroxy-2-methyl- propyl)-piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl } -1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2-hydroxy-ethyl)- piperazin-1-yl}-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one; (S)-4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydrox y-ethylamino}-3-{6-[4-(2-hydroxy- ethyl)-piperazin-1-yl]-4-methyl- 1 H-benzimidazol-2-yl } -1H-pyridin-2-one; [4-(2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-oxo- 1,2-dihydro-pyridin-3- yl}-7-methyl-3H-benzoimidazol-5-yl)-piperazin-1-yl]-acetonitrile; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(4-fluoro-butyryl)-piperazin- 1-yl]-4-methyl- 1 H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2,2-difluoro-acetyl)- piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2-methanesulfonyl-acetyl)- piperazin- 1-yl]-4-methyl-1H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl- 1 H-benzoimidazol-2-yl]-4-[2-(3-chloro- phenyl)-2-hydroxy-ethylamino}-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-{4-[2-(1-ox0-114- thiomorpholin-4-yl)-acetyl]-piperazin-1-yl }-1H-benzoimidazol-2-yl)- 1H-pyridin-2- one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-(6-{4-[2-(1,1-dioxo-116- thiomorpholin-4-yl)-acetyl]-piperazin-1-yl }-4-methyl- 1 H-benzoimidazol-2-yl)- 1H- pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3- { 4-methyl-6-[4-(2-thiomorpholin- 4-yl-acetyl)-piperazin-1-yl]-1H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 241 _ _ _ _ LC
4-[2-(3-Chloro-phenyl)-2-hydrox y-ethylamino}-3-{6-[4-(2-methanesulfinyl-acety!)- piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl}- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-{6-[4-(2-methoxy-acetyl)- piperazin-1-yl]-4-methyl-1H-benzoimidazol-2-yl}-1H -pyridin-2-one;
4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-{4-methyl-6-{4-(2-methylsulfanyl- acetyl)-piperazin-1-yl]-1H-benzoimidazol-2-yl}-1 H-pyridin-2-one; 3-{6-[4-(2-Chloro-acetyl)-piperazin- 1 -yl]-4-methyl- 1H-benzoimidazol-2-yl } -4-[2-(3- chloro-phenyl)-2-hydroxy-ethylamino]- 1H-pyridin-2-one;
(S)-4-(2-{ 4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydrox y-ethylamino]-2-oxo-1,2-
dihydro-pyridin-3-yl }-7-methyl-3H-benzimidazol-5-yl)-piperazine-1-carbaldehyde; ($)-4-(2-{4-[2-(3-Chloro-phen yl)-2-hydroxy-ethylamino]-2-oxo-1 ,2-dihydro-pyridin- 3-yl}-7-methyl-3H-benzimidazol-5-yl)-piperazine-1 -carbaldehyde; (§)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino)-3-(4-methyl-6-morpholin-4-yl- 1H-benzoimidazol-2-yl)-1 H-pyridin-2-one;
4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin- 4-yl-1H-benzoimidazol-2-yl)- IH-pyridin-2-one; 4-[2-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4- yl-1H-benzoimidazol-2-yl)- 1H-pyridin-2-one; 4-[2-(3-Chloro-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-
4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one; 4-[2-(7-Bromo-2,3-dihydro-benzofuran-5-yl)-2-hydrox y-ethylamino]-3-(4-methyl-6- morpholin-4-yl-1H-benzoimidazol-2-yl)- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2(S)-hydroxy-ethylamino}-3-[4-methyl-6-[2(S),6(R)- dimethyl-morpholine-4-yl]-1H-benzoimidazol-2-yl]- 1 H-pyridine-2-one;
4-[2-(3-Bromo-4-methoxy-phenyl)-2(S)-hydroxy-ethylamino]-3-[4-methyl-6- [2(S).6(R)-dimethyl-morpholine-4-yl}-1H-benzoimidazol-2-yl]- 1H-pyridine-2-one; 4-[2-(3-Chloro-phen y1)-(S)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2-fluoromethyl- morpholin-4-yl]-4-methyl- 1H-benzimidazol-2-yl }- 1H-pyridin-2-one and 4-[2-(3- chloro-phenyl)-(S )-2-hydroxy-ethylamino}-3-{6-[(S )-2-fluoromethyl-morpholin-4-yl]-
4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one; 4-[2-(3-Bromo-4-methoxy-phenyl)-(5)-2-h ydroxy-ethylamino]-3-{6-[(R )-2- fluoromethyl-morpholin-4-yl]-4-methyl-1 H-benzimidazol-2-yl }-1H-pyridin-2-one and 4-[2-(3-bromo-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-{(S)-2- fluoromethyl-morpholin-4-yl1]-4-methyl- 1 H-benzimidazol-2-yl } - 1H-pyridin-2-one; 4-[2-(3-Chloro-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2-
fluoromethyl-morpholin-4-yl}-4-methyl- 1 H-benzimidazol-2-yl } - | H-pyridin-2-one . 5 and 4-[2-(3-chloro-4-methoxy-phenyl)-(S)-2-hydrox y-ethylamino]-3-{ 6-[(S)-2-
fluoromethyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl } -1H-pyridin-2-one; 4-[2-(7-Bromo-2,3-dihydro-benzofuran-4-yl)-(5)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2- fluoromethyl-morpholin-4-yl]-4-methyl- 1 H-benzimidazol-2-yl } - 1H-pyridin-2-one and 4-[2-(7-bromo-2,3-dihydro-benzofuran-4-yl)-(§)-2-hydrox y-ethylamino}-3-{ 6-
[(S)-2-fluoromethyl-morpholin-4-yl]-4-methyl- 1 H-benzimidazol-2-yl }- 1H-pyridin-2- one; 4-[2-(3-Chloro-phenyl)-(S)-2-hydroxy-ethylamino}-3-{6-[(R)-2-hydroxymethyl- morpholin-4-yl]-4-methyl- 1H-benzimidazol-2-yl }- 1H-pyridin-2-one and 4-[2-(3- chloro -phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-[(S)-2-hydroxy-methyl-morpholin-4-
yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one; 4-[2-(3-Bromo-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2- hydroxymethyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl } -1H-pyridin-2-one and 4-[2-(3-bromo-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3- {6-[( S)-2- hydroxy-methyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one;
4-[2-(3-Chloro-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2- hydroxymethyl-morpholin-4-yl}-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one and 4-[2-(3-chloro-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-[(S)-2- hydroxy-methyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-(S)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2-methyl-morpholin-4-
yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one and 4-[2-(3-chloro-phenyl)- (8)-2-hydroxy-ethylamino]-3-{ 6-[(S)-2-methyl-morpholin-4-yl]-4-methyl-1H- benzimidazol-2-yl}-1H-pyridin-2-one; 4-[2-(3-Bromo-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-[(R)-2-methyl-
: morpholin-4-yl]-4-methyl- 1H-benzimidazol-2-yl}-1H-pyridin-2-one and 4-[2-(3- bromo-4-methoxy-phenyl)-($)-2-hydroxy-ethylamino]-3-{6-[(S)-2-methyl-morpholin- 4-yl]-4-methyl-1H-benzimidazol-2-yl }- 1 H-pyridin-2-one;
4-[2-(3-Chloro-4-methoxy-phenyl)-(5)-2-hydrox y-ethylamino]-3-{6-[(R)-2-methyl- morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl }- 1H-pyridin-2-one and 4-[2-(3- chloro-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino}-3-{6-[(S )-2-methyl-morpholin- 4-yl]-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one;
4-[2-(3-Chloro-phenyl)-(5)-2-hydroxy-ethylamino]-3-{ 6-[(R)-2-methox ymethyl- morpholin-4-yl}-4-methyl- 1H-benzimidazol-2-yl }- 1H-pyridin-2-one and 4-{2-(3- chloro -phenyl)-(5)-2-hydroxy-ethylamino}-3-{6-[(S)-2-methoxy-methyl-morpholin- 4-yl]-4-methyl-1H-benzimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Bromo-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-[(R)-2-
methoxymethyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one and 4-[2-(3-bromo-4-methoxy-phenyl)-(5)-2-hydrox y-ethylamino]-3-{ 6-[(S)-2- methoxymethyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl } - 1H-pyridin-2-one; 4-[2-(3-Chloro-4-methoxy-phenyl)-(S)-2-hydroxy-ethylamino]-3-{6-[(R)-2- methoxymethyl-morpholin-4-yl]-4-methyl-1H-benzimidazol-2-yl }-1H-pyridin-2-one and 4-[2-(3-chloro-4-methoxy-phenyl)-(S)-2-hydrox y-ethylamino]-3-{ 6-[(S)-2- methoxymethyl-morpholin-4-yl]-4-methyl- 1 H-benzimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2(S)-hydroxy-ethylamino)-3-[4-methyl-6-(4-methyl-
piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-pyridine-2-one; 4-[2-(3-Bromo-4-methoxy-phenyl)-2(S)-hydroxy-ethylamino}-3-[4-methyl-6-(4-
methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-pyridine-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(acetamido)- piperidin-1-yl]- 4-methyl-1H-benzoimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-hydroxyacetamido)- piperidin- 1-yl]-4-methyl- 1H-benzoimidazol-2-yl }- | H-pyridin-2-one;
4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-fluoroacetamido)-
piperidin-1-yl]-4-methyl-1H-benzoimidazol-2-yl }-1H-pyridin-2-one; oo 4-[2-(3-Bromo-4-methox y-phenyl)-2-hydroxy-ethylamino}-3- { 6-[4-(acetamido)- piperidin-1-yl]-4-methyl-1H-benzoimidazol-2-yl } -1H-pyridin-2-one; 4-[2-(3-Bromo -phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2-hydroxyacetamido)-
piperidin-1-yl]-4-methyl-1H-benzoimidazol-2-yl }- 1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3- {6-[4-(2-fluoroacetamido)- piperidin-1-yl}-4-methyl- 1 H-benzoimidazol-2-yl } -1H-pyridin-2-one;
D 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2- methoxyethoxycarbamoyl)- piperidin -1-yl]-4-methyl-1H-benzoimidazo!-2-yl}-1H- pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(methox ycarbamoy!)- : 5 piperidin -1-yl]-4-methyl- 1H-benzoimidazol-2-yl }-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{ 6-[4-(2-fluoroethox y carbamoyl)- piperidin -1-yl]-4-methyl-1H-benzoimidazol-2-yl }-1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino}-3-{4-methyl-6-(2-morpholin-4-yl- ethoxy)-1H-benzimidazol-2-yl}- 1H-pyridin-2-one; (5)-4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydroxy-ethylamino]-3-[4-methyl-6-(2- morpholin-4-yl-ethoxy)- 1H-benzimidazol-2-yl]-1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[4-methyl-6-(2-methox y- ethoxy)-1H-benzimidazol-2-yl]- 1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{4-methyl-6-(2-hydroxy- ethoxy)-1H-benzimidazol-2-yl}-1H-pyridin-2-one; (8)-4-[2-(3-Bromo-4-methoxy-phenyl)-2-hydrox y-ethylamino]-3-[4-methyl-6-(2- morpholin-4-yl-propoxy)-1H-benzimidazol-2-yl]-1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{4-methyl-6-(2-morpholin-4-yl- propoxy)-1H-benzimidazol-2-yl]- 1 H-pyridin-2-one; (5)-3-(4-Bromo-6-morpholin-4-ylmethyl-1H-benzimidazol-2-yl)-4-[2-(3-chloro- phenyl)-2-hydroxy-ethylamino]- 1 H-pyridin-2-one; (S)-3-[4-Bromo-6-(4-methyl-piperazin- 1-ylmethyl- 1 H-benzimidazol-2-yl)-4-[2-(3- chloro-phenyl)-2-hydroxy-ethylamino]-1H-pyridin-2-one; (8)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[{4-methyl-6-(4-methyl- : piperazin-1-ylmethyl)-1H-benzimidazol-2-yl}-1H-pyridin-2-one; 4-[2-(3-Chloro-phenyl)-2(S)-hydroxy-ethylamino]-3-[4-methyl-6-(1,4,5,6- tetrahydropyrimidine-1-yl)-1H-benzoimidazol-2-yl]-1H-pyridine-2-one; and 4-[2-(4-Methoxy-3-Chloro-phenyl)-2(S)-hydrox y-ethylamino]-3-[4-methyl-6- : (1,4,5,6-tetrahydropyrimidine-1-yl)- 1 H-benzoimidazol-2-yl]- 1H-pyridine-2-one.
50. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
51. The pharmaceutical composition according to claim 50 further comprising at least one other anti-cancer agent formulated as a fixed dose.
52. The pharmaceutical composition according to claim 51, wherein said anti- cancer agent is selected from the group consisting of: tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate, anastrozole, letrazole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, goserelin acetate, luprolide, finasteride, herceptin, methotrexate, 5-fluorouracil, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotephan, vincristine, taxol, taxotere, etoposide, teniposide, amsacrine, irinotecan, topotecan, an epothilone, Iressa, OSI1-774, angiogenesis inhibitors, EGF inhibitors, VEGF inhibitors, CDK inhibitors, Herl and Her?2 inhibitors and monoclonal antibodies.
53. A method of treating a condition associated with at least one tyrosine kinase enzyme comprising administering to a mammalian species in need of such treatment an effective amount of a compound according to claim 1.
54. The method according to claim 53 wherein said tyrosine kinase enzyme is Abl, CDK’s, EGF, EMT, FGF, FAK, Flk-1/KDR, HER-2, IGF-1R, IR, LCK, MET, PDGF, Src, or VEGF.
55. The method according to claim 53 further comprising administering to said mammalian species at least one other anti-cancer agent in combination with said compound.
56. The method according to claim 53 wherein the condition is cancer. .
‘ ‘e " PCT/US02/09402
57. Use according to claim 53 wherein the condition is cancer.
58. Use of a compound according to claim 50 or a composition according to claim 51 or 52 in the manufacture of a medicament for treating cancer.
59. Use of a compound according to claim 50 or a composition according to claim 51 or 52 in the manufacture of a medicament for treating proliferative diseases.
60. A substance or composition for use in a method for treating a condition associated with at least one tyrosine kinase enzyme, said substance or composition comprising a compound according to claim 1, and said method comprising : administering to a mammalian species in need of such treatment an effective amount of said substance or composition.
61. A substance or composition for use in a method of treatment according to claim 60 wherein said tyrosine kinase enzyme is Abl, CDK’s, EGF, EMT, FGF, FAK, Flk-1/KDR, HER-2, IGF-1R, IR, LCK, MET, PDGF, Src, or VEGF.
62. A substance or composition for use in a method for treating a condition associated with at least one tyrosine kinase enzyme, said substance or composition comprising a compound according to claim 1 and at least one other anti-cancer agent, and said method comprising administering said substance or composition to a mammalian species.
63. A substance or composition for use with at least one other anti-cancer agent in a method for treating a condition associated with at least one tyrosine kinase enzyme, said substance or composition comprising a compound according to claim 1, and said method comprising administering said substance or composition and said other agent to a mammalian species. 247 AMENDED SHEET
“ Se ) PCT/US02/09402
64. A substance or composition for use in a method of treatment according to claim 60 wherein the condition is cancer.
65. A substance or composition for use in a method for treating cancer, said substance or composition comprising a compound according to claim 50 or a composition according to claim 51 or 52, and said method comprising administering to a mammalian species in need of such treatment, a therapeutically effective amount of said substance or composition. :
66. A substance or composition for use in a method for treating proliferative diseases, said substance or composition comprising a compound according to claim : 50 or a composition according to claim 51 or 52, and said method comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of said substance or composition.
67. A compound according to any one of claims 1 to 49, substantially as herein described and illustrated.
68. A composition according to claim 50, substantially as herein described and illustrated.
69. Use according to any one of claims 53 to 59, substantially as herein described and illustrated.
70. A substance or composition for use in a method of treatment according to any one of claims 60 to 66, substantially as herein described and illustrated. 248 AMENDED SHEET
) PCT/US02/09402
71. A new compound, a new composition, a new use of a compound as claimed in claim 1 or a composition as claimed in claim 50, or a substance or composition for a new use in a method of treatment, substantially as herein described.
5 . 249 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27932701P | 2001-03-28 | 2001-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200307466B true ZA200307466B (en) | 2005-01-13 |
Family
ID=23068491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200307466A ZA200307466B (en) | 2001-03-28 | 2003-09-25 | Novel tyrosine kinase inhibitors. |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1381598A4 (en) |
JP (1) | JP2004534010A (en) |
KR (1) | KR20030083016A (en) |
CN (1) | CN1514833A (en) |
AR (1) | AR035804A1 (en) |
BG (1) | BG108206A (en) |
BR (1) | BR0208373A (en) |
CA (1) | CA2442428A1 (en) |
CZ (1) | CZ20032615A3 (en) |
EE (1) | EE200300475A (en) |
GE (1) | GEP20053660B (en) |
HR (1) | HRP20030844A2 (en) |
HU (1) | HUP0400323A2 (en) |
IL (1) | IL158041A0 (en) |
IS (1) | IS6968A (en) |
MX (1) | MXPA03008690A (en) |
NO (1) | NO20034308L (en) |
PE (1) | PE20021015A1 (en) |
PL (1) | PL373300A1 (en) |
RU (1) | RU2003131693A (en) |
SK (1) | SK12002003A3 (en) |
UY (1) | UY27234A1 (en) |
WO (1) | WO2002079192A1 (en) |
YU (1) | YU84603A (en) |
ZA (1) | ZA200307466B (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
WO2003073841A2 (en) | 2002-03-01 | 2003-09-12 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
JP2005532368A (en) * | 2002-06-12 | 2005-10-27 | アボット・ラボラトリーズ | Melanin-concentrating hormone receptor antagonist |
EP1575580A4 (en) * | 2002-12-02 | 2009-06-10 | Arqule Inc | Method of treating cancers |
US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
EP1590339A4 (en) * | 2003-01-28 | 2007-07-25 | Smithkline Beecham Corp | Chemical compounds |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
WO2005020921A2 (en) * | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
DE102004010207A1 (en) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer |
DK1740591T3 (en) | 2004-04-02 | 2009-10-26 | Osi Pharm Inc | Heterobicyclic protein kinase inhibitors substituted with a 6,6-biocyclic ring |
AU2005316540A1 (en) * | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
US7393667B2 (en) | 2005-05-31 | 2008-07-01 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
DK1910384T3 (en) | 2005-08-04 | 2012-12-17 | Sirtris Pharmaceuticals Inc | IMIDAZO [2,1-B] THIAZOL DERIVATIVES AS SIRTUINE MODULATING COMPOUNDS |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
EP1919905B1 (en) * | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
AU2006284900A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
US7691885B2 (en) | 2005-08-29 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
WO2007026720A1 (en) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Ring-fused pyrazole derivative |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007145203A1 (en) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | Optically active 2-amino-1-(4-fluorophenyl)ethanol |
US8063225B2 (en) * | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
WO2008144345A2 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
CL2008001822A1 (en) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compounds derived from thiazolo [5,4-b] pyridine; pharmaceutical composition comprising said compounds; and use of the compound in the treatment of insulin resistance, metabolic syndrome, diabetes, among others. |
JP2010531316A (en) * | 2007-06-25 | 2010-09-24 | エフ.ホフマン−ラ ロシュ アーゲー | Benzimidazolamide derivatives as kinase inhibitors |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
NZ586756A (en) | 2008-01-22 | 2012-04-27 | Vernalis R&D Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
JP2011520970A (en) | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | Substituted imidazopyrazines and imidazotriazines |
EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
DE102010001064A1 (en) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use |
MX2011011025A (en) | 2009-04-20 | 2011-11-02 | Osi Pharmaceuticals Llc | Preparation of c-pyrazine-methylamines. |
CN102459265A (en) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | Pyrimidine inhibitors of kinase activity |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
LT2624696T (en) * | 2010-10-06 | 2017-03-10 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
JP5789888B2 (en) * | 2010-11-01 | 2015-10-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzimidazole inhibitors of leukotriene formation |
US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
JP6461118B2 (en) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
NZ714669A (en) | 2013-06-21 | 2021-07-30 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
EA201690087A1 (en) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | NEW QUINAZOLINONS AS BROMOMODENIAL INHIBITORS |
CN103936719A (en) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | Preparation method and application of benzimidazoles derivatives |
US11920164B2 (en) | 2014-07-30 | 2024-03-05 | Yeda Research And Development Co. Ltd. | Media for culturing naive human pluripotent stem cells |
WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
CN107406438B (en) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | Inhibitors of bromodomains |
AU2016249537B2 (en) * | 2015-04-16 | 2020-01-30 | Merck Patent Gmbh | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
CN117069696B (en) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | Double-target small molecule inhibitor and preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
EP1194425B1 (en) * | 1999-06-23 | 2005-08-10 | Aventis Pharma Deutschland GmbH | Substituted benzimidazole |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
-
2002
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/en unknown
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/en not_active Withdrawn
- 2002-03-26 CA CA002442428A patent/CA2442428A1/en not_active Abandoned
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/en unknown
- 2002-03-26 SK SK12002003A patent/SK12002003A3/en not_active Application Discontinuation
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/en not_active Application Discontinuation
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/en not_active Application Discontinuation
- 2002-03-26 YU YU84603A patent/YU84603A/en unknown
- 2002-03-26 IL IL15804102A patent/IL158041A0/en unknown
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/en not_active IP Right Cessation
- 2002-03-26 CN CNA028105168A patent/CN1514833A/en active Pending
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/en unknown
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/en active Application Filing
- 2002-03-26 EP EP02723631A patent/EP1381598A4/en not_active Withdrawn
- 2002-03-26 EE EEP200300475A patent/EE200300475A/en unknown
- 2002-03-26 PL PL02373300A patent/PL373300A1/en not_active Application Discontinuation
- 2002-03-27 UY UY27234A patent/UY27234A1/en not_active Application Discontinuation
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/en not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/en not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 BG BG108206A patent/BG108206A/en unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/en not_active Application Discontinuation
- 2003-09-26 IS IS6968A patent/IS6968A/en unknown
- 2003-10-17 HR HR20030844A patent/HRP20030844A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL373300A1 (en) | 2005-08-22 |
KR20030083016A (en) | 2003-10-23 |
YU84603A (en) | 2006-03-03 |
CA2442428A1 (en) | 2002-10-10 |
IS6968A (en) | 2003-09-26 |
CZ20032615A3 (en) | 2004-03-17 |
HUP0400323A2 (en) | 2005-11-28 |
UY27234A1 (en) | 2002-10-31 |
WO2002079192A1 (en) | 2002-10-10 |
AR035804A1 (en) | 2004-07-14 |
SK12002003A3 (en) | 2004-10-05 |
JP2004534010A (en) | 2004-11-11 |
BG108206A (en) | 2004-11-30 |
NO20034308D0 (en) | 2003-09-26 |
NO20034308L (en) | 2003-11-26 |
HRP20030844A2 (en) | 2005-08-31 |
EP1381598A4 (en) | 2008-03-19 |
EE200300475A (en) | 2004-02-16 |
RU2003131693A (en) | 2005-05-10 |
IL158041A0 (en) | 2004-03-28 |
GEP20053660B (en) | 2005-11-10 |
EP1381598A1 (en) | 2004-01-21 |
PE20021015A1 (en) | 2002-11-10 |
MXPA03008690A (en) | 2003-12-12 |
BR0208373A (en) | 2005-02-22 |
CN1514833A (en) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200307466B (en) | Novel tyrosine kinase inhibitors. | |
US7081454B2 (en) | Tyrosine kinase inhibitors | |
US7470696B2 (en) | Tyrosine kinase inhibitors | |
AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
JP5977779B2 (en) | 2- (2,4,5-substituted-anilino) pyrimidine compounds | |
US7642278B2 (en) | Indazole benzimidazole compounds | |
US7691855B2 (en) | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | |
US7232826B2 (en) | Tyrosine kinase inhibitors | |
US20030207883A1 (en) | Indazole benzimidazole compounds | |
KR20060129040A (en) | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation | |
NZ523388A (en) | Cinnoline compounds | |
NZ523987A (en) | Indole, azaindole and indazole derivatives having VEGF inhibiting activity | |
WO2024184520A1 (en) | Biarylamide derivatives and their use in the treatment of proliferative disorders | |
AU2002254399A1 (en) | Novel tyrosine kinase inhibitors | |
NZ720726B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments |